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Background: Uganda’s decrease in mother-to-child transmission of HIV (MTCT) has 
stagnated, making it almost impossible to achieve the target of zero new HIV infections.  
Objectives: The aim of this study has been to determine, among a group of HIV infected 
women enrolled on universal antiretroviral treatment in Lira, Northern Uganda, the 
prevalence and factors associated with: a) unintended pregnancy, b) detectable viral load, c) 
infant nevirapine prophylaxis, and d) exclusive breastfeeding. 
Methods: A survey of 518 HIV infected pregnant women in 2018 was to determine the 
prevalence and predictors for unintended pregnancy. Of the 518, 420 had their viral load 
monitored, from which we determined the risk factors for detectable viral load. These 
women were followed up on delivery and at 6 weeks, when 472 mothers and their babies 
were included in a prospective cohort analysis to measure barriers and enablers of adherence 
to infant nevirapine prophylaxis. The mother-infant pairs were followed up until 14 weeks, 
at which point the incidence and risk factors for non-exclusive breastfeeding was 
longitudinally measured. Data was analysed using logistic regression models and 
generalised estimation equations for the Poisson family.  
Results: Of the 518 women enrolled in the study, 213 (41.1%) had unintended pregnancy 
(95% Confidence interval (CI): 36.8% - 45.5). Risk factors for unintended pregnancy were 
being single (adjusted odds ratio (AOR) = 3.74, 95% CI: 1.67 – 8.34), higher parity (parity 
of ≥5; AOR= 2.79, 95% CI: 1.85 – 4.22) and long-term ART (≥10 years; AOR=3.69, 95% 
CI: 1.57 – 8.67). Detectable viral load (>50 copies/ml) was prevalent among 120 women 
[120/420; 30.7%: 95% CI: 26.3 - 35.4%)] and viral non-suppression (>1000 copies/ml) was 
at 8.1% (34/420; 95% CI: 5.7 – 11.1%). Factors associated with detectable viral load that 
did not belong to the Lango ethnicity were: (other ethnicity: AOR = 1.92, 95% CI: 1.05 – 
3.90), and taking a second-line regimen (protease inhibitor-based: AOR = 4.41, 95% CI: 
1.13 – 17.22). A number of the infants did not keep to their nevirapine prophylaxis at 6 
weeks of age (70/472; 14.8%, 95% CI: 11.7-18.4%). Barriers to infant adherence were 
younger maternal age (≤20 years; adjusted risk ratio (ARR) =1.55; 95% CI: 1.1 – 2.2), did 
not take a viral load test during pregnancy (ARR: 1.4; 95% CI: 1.1 – 1.7), and mothers not 
receiving nevirapine syrup for the baby after childbirth (ARR = 6.2; 95% CI: 5.1 – 7.6). 
Enablers were maternal characteristics including: having attained ≥14 years of schooling 




(ARR = 0.7; 95% CI: 0.5 – 0.9), taking a nevirapine-based regimen (ARR = 0.6; 95% CI: 
0.4 – 0.9), being on long-term ART (≥ 60 months ARR = 0.75; 95% CI: 0.6 – 0.9), being 
accompanied by a husband to hospital during labour and childbirth (ARR = 0.5; 95% CI: 
0.4 – 0.7) and labour pains starting at night (ARR = 0.7; 95% CI: 0.6 – 0.8). The rate of 
exclusive breastfeeding decreased with increasing age of the infants, and by 14 weeks of age 
almost half were not exclusively breastfeeding (200/466; 42.9%, 95% CI: 38.3-47.5%). Risk 
factors for non-exclusive breastfeeding included the mother: belonging to the highest 
socioeconomic strata (ARR = 1.5, 95% CI: 1.01 – 2.1), delivering under the supervision of a 
non-health worker (ARR=1.6, 95% CI: 1.01 – 2.7), and the mother not adhering to her ART 
during pregnancy (ARR=1.3, 95% CI: 1.01 – 1.7).  
Conclusion: HIV infected women at risk of infecting their infants include the younger age 
group, unmarried, non-native to Lira, non-adherent to ART, have recently just began taking 
ART, had deliveries unsupervised by a health worker, and those that did not receive 
nevirapine syrup for their infant after childbirth. We recommend that attention should be 
focused on these critical groups during the implementation of PMTCT programs in Lira, 
Northern Uganda and in contexts similar to it. 




































The process by which infants start to ingest other foods when breast 
milk alone is insufficient to meet their nutritional requirements, and 
therefore other foods and liquids are needed alongside breast milk. 
This usually refers to the period after 6 months of age 
Contraception Any behavioural and technological methods used to avoid 
pregnancy that may be the result of vaginal intercourse 
Detectable viral 
load 
HIV infected pregnant woman on ART having a viral load count of 
50 or more copies per ml blood 
Exclusive 
breastfeeding 
An infant only receiving breast milk without any additional food or 
drink, not even water with the exception of the nevirapine syrup for 
prophylaxis or other medication within 1 h of birth and thereafter 
for 6 months 






A birth or delivery taking place at a health facility under the 
supervision of a skilled birth attendant, who is mainly a health 
worker. 
Family planning A comprehensive medical education that enables individuals to 
determine freely the number and spacing of their children, and to 
select the means (contraceptive methods) by which this may be 
achieved. This education may also involve the choice of having no 
children and the age at which to have them. 
Highly effective 
contraception 
Maintaining a level, dose or concentration of a hormonal 
contraceptive in the blood that is optimal for the prevention of 
conception. 
HIV viral load 
non-suppression 
When an HIV infected pregnant woman who is on ART and has a 
viral load count of 1000 or more copies of HIV-RNA per ml blood 
Home delivery A birth or delivery that has taken place in a non-hospital setting, e.g. 
at the traditional birth attendant (TBA) at home or on the roadside, 




The degree to which a person's behaviour corresponds with the 
agreed recommendations from a healthcare provider. 
Mixed feeding An infant receiving both breast milk and any other liquid or solid 




Products or medical procedures that interfere with reproduction 
resulting from acts of sexual intercourse 
Option B+ An approach to the prevention of mother-to-child transmission of 
HIV-1 for HIV infected pregnant women in which these women are 
immediately offered treatment for life, regardless of their CD4 
count. 
Pre-lacteal feed Any food except the mother’s breast milk that is given or fed to a 
newborn in the first few days of life 
Replacement 
feeding 
The infant receives no breast milk and is being fed suitable breast 
milk substitutes in the form of an infant formula 
Undetectable viral 
load 
HIV infected pregnant woman on ART with a viral load count <50 
copies per ml blood 
Unintended 
pregnancy 
A pregnancy that is mistimed, unplanned or unwanted at the time of 
conception 
Universal ART Initiation of HIV infected persons on lifelong highly active 
antiretroviral therapy (HAART), irrespective of the CD4 count or 
immune status 
Unmet need for 
contraception 
A situation in which those who want to stop or delay childbearing 
are not using or do not have access to any method of contraception 
Viral load the number of copies of HIV-RNA in 1 ml blood 
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Globally, the number of people living with the human immunodeficiency virus (HIV) 
increased from 36.7 million in 2016 to 38 million in 2019 (1). The prevalence of HIV in 
Uganda has been stable around 6.2% over the last half decade (2). Women are 
disproportionately affected by HIV in Uganda with 59.2% of adults living with HIV being 
women. In 2018, the HIV prevalence among Ugandan women was 7.1% compared to 4.4% 
among men. About 14,000 young women aged 15 – 24 years got infected in 2018 alone 
compared to 5,000 new infections among young men (2). Scrutinizing the statistics further, 
the HIV prevalence in mid-northern Uganda (Lango sub-region) is at 7.2% and Lira district 
has an antenatal HIV prevalence of 13.5%, which is by far the highest prevalence among 
sentinel sites located in major urban areas in Uganda (3). HIV infected women of 
reproductive age are at risk of passing on the HIV infection to their offspring when 
pregnant, giving birth or breastfeeding. Mother-to-child transmission (MTCT) of HIV is the 
main mode of HIV transmission among children under 15 years of age, the majority of these 
infections occurring in sub-Saharan Africa (4). In 2017 alone, 180,000 children became 
HIV infected in the 23 high priority countries, of which Uganda is one. Uganda contributed 
3.3% to these new infections. The majority of these infections were by vertical transmission 
(5). With antiretroviral medications for prevention of mother-to-child transmission of HIV 
(PMTCT), the majority of mother-to-child transmitted HIV infections are preventable. 
Uganda has made significant progress towards PMTCT, which is evident by the 86% 
reduction in new infections among children between 2010 and 2016 (6). However, the 
proportion of HIV exposed infants who get tested for HIV remains at 45% due to low 
retention of mother-infant pairs in the PMTCT programs in Uganda (7). Keeping women 
and their infants in PMTCT programs after delivery has been a challenge and more infant 
infections have occurred during breastfeeding than during pregnancy because women do not 
remain in care (8).  
HIV treatment and monitoring 
HIV is treated with antiretroviral drugs that stop the virus from replicating in the body thus 
preventing further damage. Antiretroviral therapy is prescribed in triplicate combination 
including different classes of drugs to prevent the virus from becoming resistant to any one 




of the medications (9). The Ugandan HIV treatment and care program has implemented the 
‘test and treat’ policy which calls for initiation of antiretroviral therapy (ART) immediately 
after an HIV diagnosis is made in an effort to eliminate HIV transmission and improve 
quality of life for people living with HIV (PLH) (10). HIV infected individuals taking ART 
benefit from HIV monitoring from which response to ART can be checked and HIV drug 
resistance detected early enough to impede ART failure. HIV monitoring is both clinical 
and laboratory-based. Clinical monitoring involves staging of HIV using either the presence 
or absence of HIV-related signs using the WHO staging system (9). Laboratory monitoring 
of HIV involves conducting a number of tests. A CD4 count test helps to find out the status 
of the immune system to gauge the risk for complications and opportunistic infections. Viral 
load tests primarily aid in monitoring the patient’s response to ART and act as a proxy for 
disease progression. Organ function tests, like liver and renal function tests, are also 
conducted to monitor for drug toxicity, ART-related metabolic changes and HIV 
comorbidities like hepatitis B or C (11). Drug resistance testing checks whether the virus is 
resistant to the ART drugs due to mutations and consequently ART failure.  
Evolution of PMTCT  
The World Health Organization’s (WHO) four-pronged approach to PMTCT (12) is based 
on:  
1) prevention of new HIV infections among women of childbearing age (15-49 years)  
2) prevention of unintended pregnancies among women living with HIV (WLH)  
3) prevention of HIV transmission from women living with HIV (WLH) to their 
offspring  
4) providing appropriate treatment, care and support to WLH, their children and 
families.  
The third prong has been the primary focus for PMTCT programs for several years, giving 
less emphasis to prongs 1, 2 and 4. PMTCT treatment guidelines have dramatically changed 
several times in the past decades. WHO guidelines for prophylactic ARV regimens have 
progressed from single-dose nevirapine (NVP) to short course zidovudine (AZT); AZT-
based “Option A”; to “Option B,” which means initiation of triple-drug antiretroviral 
therapy (ART) to the mother during pregnancy through breastfeeding; and the subsequent 
“Option B+,” pioneered in Malawi - nowadays often called “universal ART for all”- where 




all HIV-infected pregnant and breastfeeding women are initiated on lifelong ART 
irrespective of the number of CD4+ T-lymphocytes in the blood (CD4 count) or clinical 
stage (9,13) Table 1. With each change, Uganda has attempted to harmonize its guidelines 
with the global recommendations. Over time, this has resulted in confusion, with success 



































































The current PMTCT (option B+) program takes the form of a cascade or steps of 
interventions (14) designed to collectively reduce or virtually eliminate the risk of MTCT of 
HIV among mother-infant pairs (Figure 1).  







As women of known and unknown HIV status move along the cascade while receiving care 
through health service, each stage or intervention of the cascade is an opportunity for HIV 
prevention. However, if a woman misses out on any opportunity for HIV prevention as 














The preconception period avails an opportunity for HIV testing for the woman to know her 
HIV status. In this period, the woman also has a choice to plan for the timing and spacing of 
her births by using contraception, which is fully available through the integration of family 
planning services into HIV care (13). Preventing unintended pregnancies will reduce the 
number of infants that could potentially acquire HIV from their mothers and subsequently 
reduce the number of children that may require HIV services (15,16). Once a WLH 
becomes pregnant, she should initiate adequate prenatal care through receipt of ANC at 
PMTCT clinics that are usually located within public health facilities in Uganda. Antenatal 
care also avails an opportunity for HIV testing for all pregnant women, timely initiation of 
ART for life for all newly diagnosed women, and subsequently routine virologic monitoring 
to assess ART adherence and potential HIV drug resistance arising from ART failure. High 
maternal viremia is an important risk factor for MTCT and must be promptly addressed in 
WLH that intend to or those already pregnant (17–19). For pregnant WLH, facility delivery 
is emphasized to reduce on the risk of MTCT by availing the opportunity for skilled birth 
attendance during delivery (4). Skilled birth attendance avails the opportunity to prevent 
complications that arise during pregnancy and childbirth, to prevent maternal and neonatal 
mortality or morbidity. Most importantly, facility delivery has a number of benefits for the 
WLH: 1) it promotes the timely initiation of nevirapine prophylaxis for the baby; 2) it 
creates an atmosphere for continuous reinforcement of counselling messages on infant 
feeding, adherence to maternal ART and infant prophylaxis.(20). It is from these benefits 
that the reduction in risk of MTCT is achieved.  
Nevirapine prophylaxis is given to the infant shortly after delivery to prevent residual HIV 
transmission from a mother to the infant during delivery and breastfeeding. This form of 
pre- and post-exposure prophylaxis involves timely initiation of ART (within 72 h) to the 
infant and should achieve therapeutic levels for optimal PMTCT (21). During the 
postpartum period, other interventions - early infant diagnosis and infant HIV testing -are 
essential for the early detection of infection. This promotes prompt ART initiation in case 
the infant is infected.  
Infant feeding is crucial for all infants, whether exposed to HIV or not. Optimal infant 
feeding comprises exclusive breastfeeding (EBF) where the infant is given only breast milk 




within one hour after birth, followed by maintenance of sole breastfeeding till the HEI is 6 
months old and complementary feeding for 18 – 24 months with age appropriate foods (22). 
Pre-conception care among HIV infected women 
Fertility desires for WLH have increased over time because the PMTCT interventions 
available have enabled these women to have HIV-free babies (16,23–26). It is therefore 
important to support WLH in their fertility choices through family planning. Much as 
integration of family planning into HIV services exists, the unmet need for contraception 
persists, resulting in continuing high rates of unintended pregnancy (26–30). Surprisingly, 
the rates of unintended pregnancy among WLH in sub-Saharan Africa are higher (35 – 
71%) (16,23,38,39,29,31–37) compared to rates in the general population (26 – 34%) 
(40,41). This is probably because WLH face high rates of unmet need for contraception 
ranging from 36 to 75% (29,37,39,42–45). Unintended pregnancy can also result from 
incorrect or inconsistent use of contraception, interaction of hormonal methods with ART 
making them less effective (46,47), relying on non-modern contraception and contraceptive 
failure (16,25,29,31,39,46–48).  
Various factors have been associated with unintended pregnancy among WLH, including  
younger age, being single, ethnicity, education status, higher parity, having had a previous 
abortion, late or no ANC attendance, incorrect or inconsistent use of barrier methods, 
elevated VL and long term ART use (25,31,36,38,48–51).  
HIV virologic monitoring during pregnancy 
Viral load monitoring during pregnancy is important both in assessing whether the drugs are 
taken according to prescription (ART adherence) or resistance to the drugs has developed, 
and also in the evaluation of the risk of MTCT (17,51–53). The risk of HIV transmission 
from mother-to-baby reduces with lowering maternal viremia; transmission may occur even 
with maternal HIV-1 RNA as low as 50 - 400 copies/ml blood (54). It is therefore crucial to 
maintain maternal viral load at undetectable levels (<50 copies/ml blood). Challenges 
during pregnancy, such as cultural, social and hindrances to adherence, may make it 
difficult to maintain and achieve viral suppression (51). The Ugandan guidelines 
recommend that if a pregnant woman is newly diagnosed with HIV, she must be initiated 
immediately on ART and the first viral load monitoring will be done 6 months after 




initiation, when the viral load should have decreased to an undetectable level. If instead her 
VL remains elevated (detectable but <1000 copies/ml), she will receive adherence support 
while continuing with her ART, thereafter VL monitoring is done once every year. If her 
VL is high (>1000 copies/ml), she will be offered intensive adherence counselling (IAC) 
with at least 3 sessions a month apart. A VL test is then done at the last session. If this VL is 
>1000 and found adherent, it is concluded her HIV has developed resistance and the woman 
is switched to a different ART regimen. For a pregnant woman who is already established 
on ART prior to conception, viral load testing is done at the first ANC visit and guidelines 
above apply (9,10). Unfortunately, the policy does not always translate into practice for 
viral load monitoring for HIV positive pregnant women. A considerable proportion of HIV 
infected pregnant women fail to have a viral load test done during pregnancy (55). Women 
who are newly diagnosed while pregnant are unlikely to have a viral load test done 
compared to those already established in ART prior to pregnancy (56). This is because 
women that are newly diagnosed could have been diagnosed in the later gestation during 
pregnancy, whereas those that are already established in ART care are mandated to have 
their viral load checked at the first antenatal visit. 
Various predictors for persistently high levels of maternal viremia (detectable viral load and 
viral non-suppression) among pregnant women have been highlighted in a number of 
studies. These include late engagement into ANC, poor ART adherence, receipt of NNRTIs-
based regimens, high baseline VLs, low baseline CD4 counts, ethnicity, drug abuse, 
Hepatitis C infection, unintended pregnancy, previous discontinuation of ART, medication 
concerns (side effects), MTCT of HIV, being employed, low education level, parity or 
gravidity, shorter ART duration and non-disclosure of HIV status to partner (51,57–65).  
It is challenging to compare studies that report on detectable viral load and viral suppression 
in pregnancy, since they use varying cut-off limits for HIV-RNA levels. This is because 
different virologic tests use different HIV RNA assays that have varying lower limits of 
detection. These studies have also been done in varying contexts. Furthermore, women who 
have previously achieved viral suppression can experience viral load rebound near delivery, 
which is risky for MTCT of HIV (59). It is therefore important to focus the timing for 
virologic monitoring during pregnancy nearer to delivery. Most studies looking at predictors 
for persistent maternal viremia do so for mainly higher virologic profiles (>1000) and do not 




consider detectable virologic profiles as alarming. It is these detectable viral loads that may 
eventually become unsuppressed. The threshold for detectable viral load varies, being 
determined by the lower limit of detection of the assays used for viral load testing. The 
threshold for viral non-suppression, particularly for Uganda, was adapted from the 
international guidelines for ART care and treatment (9). 
Infant ART prophylaxis for eMTCT 
It is vital for infants born to WLH to be immediately started on and remain adherent to 
prophylaxis after childbirth and through breastfeeding due to exposure to maternal HIV 
(9,10). The HEI should take prophylaxis for 6 to 12 weeks. A longer duration of prophylaxis 
is recommended for high-risk infants born to an HIV infected mother that has a viral load 
(VL) > 1000 copies/ml blood (9,10). For a high-risk infant, the mother’s VL test should be 
done at 12 weeks postpartum and only if <1000 copies/ml should the infant stop taking 
nevirapine (NVP). If the maternal VL is not suppressed by 12 weeks, the infant should 
continue taking NVP until the mother’s VL is <1000 copies/ml or otherwise continue with 
NVP until 4 weeks after cessation of all breastfeeding (10). These guidelines have been 
implemented in Uganda since 2012 (66). Challenges in achieving adequate infant adherence 
do exist and can be programmatic, maternal- or infant-related (21,67–69). Risk factors for 
non-adherence to infant nevirapine prophylaxis are: home deliveries, inadequate antenatal 
care, mother not receiving the nevirapine for her baby while at hospital, misplacing of the 
baby’s drug, lack of transport and the mother staying with in-laws (70,71).  
Infant feeding in the context of HIV 
Exclusive breastfeeding (EBF) involves giving the infant only breastmilk within the first 
hour of birth and thereafter for 6 months (72). Breast milk (including colostrum) is a 
complete food for the newborn especially for the first 6 months of life. Colostrum, which is 
the first milk immediately after childbirth, is very rich in immune substances, like the 
secretory immunoglobulin A (sIgA) and other bioactive substances that act as a first line 
defence for the infant’s immature innate immunity (72). HIV exposed uninfected and 
infected infants are 2 critical groups that can greatly benefit from exclusive breastfeeding as 
they are at greater risk of malnutrition, opportunistic infections like diarrheal and respiratory 
diseases, as well as death when compared to their HIV unexposed counterparts (73). 




Breastfeeding is a major transmission route for HIV from a mother to her infant and 
therefore it should be practiced with caution. This has led to the development of various 
guidelines to create a balance between the infant benefiting from the breastfeeding and 
preventing the acquisition of HIV (22). As in the general population, WLH should initiate 
exclusive breastfeeding for the infant within the first hour after birth and continue with it for 
6 months, and thereafter give age-appropriate complementary foods alongside the 
breastfeeding for 12 – 24 months or longer (22). 
To lower the risk of MTCT of HIV, WLH and their infants have to be supported in 
adherence to both maternal ART and infant prophylaxis while breastfeeding (9). Studies 
have demonstrated the association between various factors and infant feeding practices. 
WLH who receive counselling on infant feeding and those that disclose their HIV status are 
more likely to breastfeed exclusively their HEIs (74). Barriers to breastfeeding include 
maternal factors, like breast problems, home delivery, cultural beliefs, lack of safe water, 
lack of counselling or support during continuation of infant feeding and infant factors, e.g. 
mouth ulcers (75–78).  
The PMTCT cascade guided the development of this framework. The interplay between 
several factors increases the risk for mother-to-child transmission of HIV and subsequently 
contributes to an increase in the number of paediatric HIV infections. Individual or maternal 
factors influence outcomes, such as pregnancy intent, viral load suppression, adherence to 
infant ART prophylaxis and exclusive breastfeeding, which inadvertently heightens 
transmission risk. In addition, some of these outcomes can act as exposures. Virologic non-
suppression has been associated with unintended pregnancy (51). Home delivery is 
associated with both non-adherence to infant nevirapine prophylaxis (69) and non-exclusive 
breastfeeding (75). 
Justification for the study 
Each aspect of the PMTCT cascade is important and a deficiency in any of the interventions 
compromises the overall effectiveness, resulting in increased risk for MTCT of HIV. In this 
thesis work, we assessed particular points of the PMTCT cascade where adequate data in 
the study setting was lacking. These include unintended pregnancy, detectable viral load, 
adherence to infant nevirapine prophylaxis and infant feeding. 












Several studies on unintended pregnancy among WLH this topic have mainly looked into 
predictors for contraceptive use in the context of HIV, and merely mention the rates of 
unintended pregnancy, but very few dig deep into predictors for unintended pregnancy in 
the context of HIV. This is why investigating the rates and associated factors of unintended 
pregnancy in this context is important. Maternal viremia is an important predictor for 
MTCT of HIV. Most studies looking at predictors for persistently raised maternal viremia 
do so mainly for higher virologic profiles (>1000) and do not consider detectable viral load 
counts as alarming. It is these detectable viral loads that may eventually become 
unsuppressed and increase the risk of MTCT of HIV. It is for this reason that studying 
detectable viral load among WLH in Lira is vital.  
Poor adherence to infant nevirapine prophylaxis may contribute to MTCT of HIV. Evidence 
on adherence to infant nevirapine prophylaxis has mostly been qualitative and dates far back 
under previous treatment paradigms; it cannot be compared to today’s situation. It is 
therefore important for newer evidence on this subject to be generated, especially in Lira. 
Even with guidelines available, mixed feeding in the first 6 months of life remains a 
common practice and EBF rates among HEI remain critically low (74,75,77–80). Risk 
factors for these low rates are not well understood and vary within different contexts. The 
settings for studies that have looked at EBF in the context of HIV have been heterogeneous 
and tend to vary from country to country. It is therefore important to find out what the status 
quo on EBF among WLH is in Lira. 
It is against this background that we sought to determine the prevalence and factors 
associated with unintended pregnancy, detectable viral load, exclusive breastfeeding among 
HIV infected women enrolled on universal ART, as well as the proportion of babies born to 
HIV infected mothers that adhered to infant nevirapine prophylaxis and factors contributing 
to their non-adherence.  
  





Aim and objectives 
The aim of this thesis work was to determine among a group of HIV infected women 
enrolled on universal antiretroviral treatment in Lira, Northern Uganda, the prevalence and 
factors associated with: a) unintended pregnancy, b) detectable viral load, c) infant 
nevirapine prophylaxis, and d) exclusive breastfeeding. 
 
The specific objectives were:  
 
1. To determine the prevalence and predictors for unintended pregnancy among HIV 
infected pregnant women in Lira, Northern Uganda (Paper I) 
2. To assess the factors associated with detectable viral load among HIV infected 
pregnant women in Lira, Northern Uganda (Paper II) 
3. To identify barriers and enablers of adherence to infant nevirapine prophylaxis 
among 6-week-old HIV exposed infants in Lira district, Northern Uganda (Paper III) 
4. To determine the risk factors for non-exclusivity of breastfeeding in the first 14 
weeks of life of HIV exposed infants (Paper IV) 




Subjects and methods 
The papers relating to this thesis work originate from studies of a single prospective cohort 
of HIV infected pregnant women receiving antenatal care at Lira Regional Referral Hospital 
in Northern Uganda. Participants were recruited into the cohort during the antenatal period 
(papers I and II) and followed at birth, 6 weeks postpartum (paper III) and 14 weeks 
postpartum (paper IV), Figure 7. The methods employed are described in detail in each 
paper, and in this section, we give a summary of them. 
Study area and setting 
 
Figure 6: Lira District in Northern Uganda. 




Lira district is one of the 8 districts within the Lango sub-region of Uganda. The majority of 
the population belongs to the ethnic group, Langi, the predominant language being Lango. 
The main municipal, administrative and commercial centre in the district, Lira, is located 
350 kilometres by road north of Kampala. Lira district has 4 counties: Erute North county, 
Erute South county, Moroto county and Lira town council, as well as 28 sub-counties. There 
are 192 parishes with 2,247 villages. In 2014, Lira district was the home of 410,516 people 
(196,891 males and 213,625 females), with the municipality (the urban centre) having 
99,059 people (81).  
Lango sub-region is neighboured in the north by the great Acholi sub-region. The 
mentioned 2 sub-regions are in the great Northern region of Uganda that was severely hit by 
the great LRA insurgency (war) for over 20 years. To date, the conflict has seen more than 
10,000 people massacred or mutilated, and twice the number of women and children 
abducted and forced to work as soldiers, porters and sex slaves. About 1.8 million people 
were displaced, many of whom lived in government run camps. The war came to an end 
about 10 years ago. The war had a grave effect on various health indicators, including HIV 
as evidenced by the high HIV prevalence of 7% in the general population and high antenatal 
HIV prevalence of 13.5% (3). The effect of the insurgency on most social services, 
including health, make Lira a unique setting for research as findings in this region may be 
different from those in a more “ideal” setting.  
The district has 27 health facilities: 11 health centre IIs at parish level, 11 health centre IIIs 
at county level, 3 health centre IVs at the sub-district level and 2 hospitals (one of which is a 
regional referral hospital) (82). This study was conducted at Lira regional referral hospital 
(LRRH), which serves all 8 districts of the subregion, including Amolatar, Apac, Dokolo, 
Lira, Otuke, Alebtong, Kole and Oyam. Lira hospital serves a population of 408,043 in Lira 
district (81). It is a government-owned health facility at tertiary level, with 254 beds. LRRH 
offers health services, including promotive, preventive, curative, maternity, surgery, 
emergency, inpatient, outpatient blood transfusion and laboratory services. Maternal and 
child health services include antenatal care, delivery, postnatal care, immunisation and HIV 
care services. These services are available free for the patients (82). The services are 
categorized and offered in respective clinics/departments/wards, as outpatient and inpatient 
clinics. The HIV care services are categorized into general HIV care and PMTCT services. 




PMTCT services are offered in an independent clinic within the hospital; this is where HIV 
infected women receive antenatal and HIV care when pregnant. At the time of delivery, 
HIV infected women in Lira are free to deliver at a health facility of their choice. In LRRH, 
they deliver in the labour suite at the maternity ward, at which point the mother is supposed 
to receive nevirapine syrup for her newborn infant. However, in LRRH, HIV infected 
women that have just delivered their baby return to the PMTCT clinic with their infant for 
weighing and classifying of their newborn to determine the dosage and receive the 
nevirapine syrup for their infant. The mother-infant pairs continue to receive HIV care at the 
PMTCT clinic until the infant is 6 weeks old. However, the immunization services for the 
infant are not offered at the PMTCT clinic. The mother has to take her infant to the young 
child clinic within LRRH or another health facility of her own choice for immunization. The 
mother-infant pair is discharged from the PMTCT clinic at 6 weeks postpartum and 
transferred to the early infant diagnosis (EID) clinic, which is an independent stand-alone 
department from the PMTCT clinic. The first DNA-PCR test for infant HIV diagnosis is 
done at the EID clinic for 6-week old infants. The mother-infant pairs continue to receive 
their HIV care at the EID clinic until the infant is 18 months old, at which point the first 
HIV antibody test is done. The mother and her infant will then be discharged from the EID 
clinic when the infant is 24 months old and transferred to the general HIV care clinic.  
The LRRH also has annually an outpatient attendance of almost 100,000 patients, antenatal 
care attendance of about 5,000 women, and conducts 6,000 – 7,000 deliveries (82).  
Study design and procedures 
We screened for eligibility, consented and recruited consecutively onto the study and 
followed up HIV infected pregnant women at different time-points at the PMTCT clinic in 
LRRH. Women were eligible for participation when 20 or more weeks pregnant, newly 
tested or already established into HIV care. Women did not participate in the study if their 
partner declined their participation or they had received their ART care from another facility 
(Figure 7). To minimize loss to follow-up, information on telephone contacts and physical 
addresses were collected. All study visits except the one around the time of delivery were 
done at the PMTCT clinic and were timed to coincide with the mother’s routine visits for 
ART care. It is these time-points of follow-up that constitute the different papers described 
in the following paragraphs (Figure 7). This prospective cohort study applied quantitative 




methods to observe outcomes (unintended pregnancy, detectable viral load, adherence to 
infant nevirapine prophylaxis at 6 weeks, exclusive breast feeding at 14 weeks), and related 
them to other associated or risk factors.  
 
Figure 7: Flow chart of the thesis work 
Paper I and II 
These 2 studies employed a cross-sectional design and were conducted among HIV infected 
pregnant women recruited at baseline. They were interviewed on socio-demographic 
related, reproductive-related and HIV-related information, using a structured questionnaire 
and combined it with viral load tests from Uganda National Health Laboratories for those 
who had been on ART for at least 6 months. All women recruited were included in the 
analysis for paper I. Only those that had a viral load test done and results available were 
included in the analysis for paper II. These two studies were designed to investigate the 




association between a number of covariates on pregnancy intent (paper I) and detectable 





































































































This was a prospective cohort study to determine the barriers and enablers of adherence to 
nevirapine prophylaxis among 6-week-old HEI. WLH that had given birth to a live baby in 
the cohort from paper III were followed up at 6 weeks postpartum and asked about the 
infant’s adherence to nevirapine prophylaxis. A total of 472 mother-infant pairs were 
included in the final analysis for paper III.  
Paper IV 
This study employed a prospective cohort study design to determine the incidence of 
exclusive breastfeeding among HIV exposed infants from birth to 14 weeks of life, as well 
as risk factors for non-exclusive breastfeeding. The mother-baby pairs from study IV were 
followed up; when the infants were 14 weeks of age, women were asked about exclusivity 
of breastfeeding through a face-to-face interview. Complete information was obtained for 
466 mother-infant pairs and analysed for paper IV. 
Variables 
Some exposure variables were common across all the papers, one being age which was 
collected as continuous, but later categorised for each paper. Education was categorised as 0 
– 6, 7 – 10, 11 – 13 and ≥14 years of schooling; marital status was categorised into single (if 
the woman was separated, divorced, widowed or not married) and married (if the woman 
was married or cohabiting). Employment status was categorised into employed (if the 
woman was formally or self-employed) and unemployed. Religious affiliation was either 
Christian or Muslim. Ethnic belonging was either Langi (if native to the study setting) or 
else as other. Wealth quartiles were calculated using principal component analysis (PCA). 
The PCA technique is one that reduces the dimensionality of large data sets. This involves 
the transformation of a large set of variables into smaller ones by combining and ranking of 
a number of variables into smaller and fewer variables without prejudgment, while 
maintaining the original information. PCA is considered a more accurate indicator of socio-
economic status than single items, such as occupation or possession of particular items (83). 
Characteristics considered for PCA were: house ownership, availability of electricity in the 
house, source of drinking water, and fuel used for cooking. Categorization of other 
exposures was as follows: parity: ≤4 and ≥5 pregnancies ever carried, including the one at 




the time of the study; gestational age: 20 – 27, 28 – 35 and ≥36 weeks of gestation; 
accompanied by partner to ANC: accompanied or not; use of birth control: used or didn’t 
use any form of contraception 6 months prior to pregnancy; type of contraceptive used: 
none (if no contraceptive was used or relying on safe days) and effective contraception (if 
oral contraceptive, injectable contraceptive, implants, intrauterine device, condoms or 
emergency contraception was used 6 months prior to pregnancy); HIV status disclosure: 
(disclosed/undisclosed); person disclosed to: (husband/ ther); fear about others’ opinion on 
HIV status: (had fear/no fear); ART regimen (efavirenz-based, nevirapine-based or protease 
inhibitor-based) ART duration: (<6 , 7 – 30, 31 – 119 and ≥120 months) 
Paper I: The dependent variable for this study was unintended pregnancy. It was defined in 
any of the following ways; a pregnancy that occurred: when no more children were desired, 
earlier than it was desired or when the woman did not desire to become pregnant. Women 
were asked if the pregnancy came ‘earlier than expected’, ‘later than expected’, ‘when 
expected’ or ‘not desired at all’ (84). Women who had their pregnancy at the ‘time desired’ 
or ‘later than expected’ were combined, labelled as the ‘intended’ category. Women with an 
‘earlier than desired’ or ‘unwanted pregnancy’ were combined into a single group, labelled 
“unintended pregnancy”.  
Paper II: Detectable viral load, the main outcome of this study, was defined as the presence 
of copies of HIV-1 RNA per ml blood plasma of ≥50 up to 999. Viral load counts <50 
copies/ml were categorized as ‘undetectable viral load’. The presence of ≥1,000 copies/ml 
was called ‘viral non-suppression’. The independent variables maternal age, education, 
marital status, employment status, religion, ethnicity and socio-economic status, gestational 
age, accompanied to ANC by partner, use of birth control, type of contraceptive used, HIV 
status disclosure, fear about others’ opinion on HIV status, ART regimen were all 
categorised as in study I. Other exposure variables were categorised and labelled as: parity 
(1 – 4 and 5 – 9), intention to have baby: (yes/no), ART duration: (6 – 36, 37 – 119, ≥120 
months).  
Paper III: The outcome variable of interest for this paper was “non-adherence to infant 
nevirapine prophylaxis”. In the 7 days prior to the interview, infants reported by the mother 
or care giver to have missed 0 – 2 doses of their nevirapine syrup were collectively 
categorized and labelled as “adherent,” and for those reported to have missed ≥3 doses were 




collectively categorized and labelled as “non-adherent”. Exposure variables of marital 
status, employment status, religion, ethnicity, parity, gestational age, HIV status disclosure 
and ART regimen were categorised as in paper I. Other exposures were categorised as 
follows: maternal age as: ≤ 20, 21 – 29, 30 – 39 and ≥40 years; education as: ≤6, 7 – 13 and 
≥14 years of schooling; ART duration as: short-term (<60 months) or long-term (≥ 60 
months); VL count during pregnancy (<50 copies/ml, ≥50 copies/ml or missing VL test 
result); mother given nevirapine syrup for baby at delivery as: either ‘given’ or ‘not given’. 
Exposure variables categorised as in paper III are: type of delivery, time of onset of labour, 
place of delivery, person who supervised the delivery, person escorting during delivery and 
maternal ART adherence.  
Paper IV: The outcome for this paper was “non-exclusivity” of breastfeeding, which was 
measured at birth, 6 weeks and 14 weeks postpartum. Prelacteal feeding was defined as the 
baby taking any liquid other than breast milk immediately after birth, with the exception of 
medicines (e.g. nevirapine). Infants reported by their mother to have taken any liquid other 
than breast milk were considered not to be exclusively breastfeeding. At the 6- and 14-week 
visits, infants reported by their mother to have taken any liquid or solid food other than 
breast milk in the 7 days prior to the respective visits were considered not be exclusively 
breastfeeding. All the infants who were not exclusively breastfed at the various visits were 
collectively categorised as “non-exclusively breastfed” and the rest as “exclusively 
breastfed”. The exposures included in this study were: age (≤20, 20 – 21, ≥30 years); 
education level: (≤6, 7 – 13, ≥14 years); ART duration (≤6, 7 – 30, 31 – 119, ≥120 months); 
Viral load count (<50, 50 – 400, 401 – 499, >1000 copies/ml and missing viral load) 
These exposures were categorized and coded as in the previous papers: marital status, 
employment status, religion, ethnic belonging, parity, gestational age, HIV disclosure, 
socio-economic strata, antiretroviral regimen, time of onset of labour, type of delivery, place 
of delivery, person who supervised delivery, maternal adherence to ART and adherence to 
infant nevirapine prophylaxis. 
Sample size estimation 
We planned to answer several questions with the same cohort of HIV infected pregnant 
women. For each question, the expected sample size needed was calculated, and basing on 




the largest sample size with a 10% non-response rate, we recruited 518 HIV positive 
pregnant women who were receiving antenatal care at Lira Regional Referral Hospital 
(LRRH). For papers I, II, and IV, sample sizes for detecting a difference between two 
independent proportions were calculated using Stata version 14.0 (StataCorp; College 
Station, TX, USA), in particular the statistics, power and sample-size functions. We then 
used the population parameter method with the test of comparing two independent means. 
We assumed 80% power, 95% confidence interval (CI) and a 5% precision. For each of the 
respective papers, we assumed 2independent proportions specific to each outcome. 
Paper I  
For this study, it was assumed that 57.6% of WLH were not in a marital union (85) and that 
31.5% of HIV infected women were married (31). On running this calculation through the 
statistical software, a sample size of 464 women was arrived at. We adjusted the sample size 
to 516 after accounting for a 10% non-response. We however, recruited 518 participants. 
Paper II  
In this paper, it was assumed that 23% of HIV infected pregnant women had detectable viral 
load (86), and that 12% of HIV infected women with a detectable viral load were taking a 
protease inhibitor-based regimen (87). After accounting for 11% non-response, the final 
sample size was 420 HIV infected women.  
Paper III  
For this study, we estimated a sample size for detecting an unknown proportion of infants 
adhering to infant prophylaxis using OpenEpi (openepi.com). We assumed a 50% 
proportion, 80% power, 95% confidence interval (CI) and 5% precision. The total sample 
size for this study was 384 HEI. After adjusting for 10% non-response and another 10% to 
allow for enough degrees of freedom in the multivariable analysis, the final sample size was 
464; however, 472 mother-infant pairs were included.  
Paper IV 
We assumed that 70% of women (88) (Mpody, 2019) received EBF support and counselling 
at delivery, and that 42.5% of women were not advised or counselled on exclusive 
breastfeeding during pregnancy (89). The total sample size for this study was 418 HEI. 




After accounting for 10% non-response, the final sample size was 464; however, 466 HEI 
were included. 
 
Data collection procedure and tools used 
Data analysis 
For all papers, data were entered into EpiData software (www.epidata.dk, version 4.4.3.1) 
by 2 independent data entrants and analyzed with Stata version 14.0 (StataCorp, College 
Station, Texas, U.S.A.). Continuous data, if normally distributed, was summarised into 
means and standard deviations; if skewed, it was summarized into medians with their 
corresponding interquartile ranges. Categorical variables were summarized into frequencies 
and percentages. The proportion (incidence or prevalence) of HIV infected women with the 
outcome of interest in each paper was estimated and its confidence limits calculated using 
the exact method. 
Papers I and II:  
We used multivariable generalized linear model regression analysis with a logit link to 
estimate adjusted odds ratios with corresponding confidence intervals of the exposures for 
unintended pregnancy (paper I) and detectable viral load (paper II), while controlling for 
confounders. Variables with a p<0.25 at the bivariate level were include in the initial model 
at the multivariable analysis. All variables with p<0.1 and those with biological or 
epidemiological plausibility were included in the second model. We checked if the second 
model was significantly different from the initial model using the likelihood ratio test. If 
there was no difference, then the second model was adapted as the final model (90). All 
exposures without the null value in their corresponding 95% confidence intervals were 
considered to be associated with the outcome. We checked for confounders by calculating 
the percentage change in each effect measure while removing and introducing one variable 
at a time from the model. If a variable caused >10% change in any effect measure, it was 
considered a confounder.  
 
 




Paper III and IV 
Poisson regression models/analysis were used for bivariate and multivariate analyses (91) to 
estimate unadjusted and adjusted odds ratios with corresponding confidence intervals of the 
exposures for the respective outcomes (adherence to infant nevirapine prophylaxis and non-
exclusivity of breastfeeding). We used a similar process for model building, while 
controlling for confounders as for papers I and II (90) 
Ethics 
Approval to conduct all the studies was granted by the following approving authorities:  
1) Makerere University College of Health Sciences School of Medicine Research and Ethics 
(SOMREC) committee; approval number: REC REF No. 2017-004; 10 January 2018  
2) Uganda National Council for Science and Technology; approval number: HS222ES; 24th 
September 2018  
3) Norwegian Regional Committee for Medical and Health Research Ethics in the West; 
approval number: 2017/2489/REK vest; 26th January 2018.  
Administrative clearance was granted by the Lira district health officer and LRRH. Service 
providers/counsellors at the PMTCT clinic were introduced to the study and its procedures, 
and were requested to identify, mobilize and link willing participants with the research 
team. Participants received verbal and written information detailing the purpose and process 
of the study. All participants provided written informed consent confirming their voluntary 
participation in the study. Those that declined participation were neither penalized nor 
denied standard healthcare. Confidentiality and privacy of all data collected was observed 
during the course of the study through restricted access. 




Summary of results 
Study flow chart 
A total of 547 HIV infected women were screened for eligibility, of which 518 were 
included in the study as the baseline cohort. It is from this baseline cohort that 2 outcomes 
were measured: 1) unintended pregnancy (Paper I); 2) detectable viral load (Paper II). This 
cohort was followed up until delivery time (n=505) and at 6 weeks postpartum (n=472), at 
which point adherence to infant nevirapine prophylaxis was assessed. When the infants 
were 14 weeks old (n=466), the outcome of exclusive breastfeeding was measured. Reasons 
for exclusion of women at the different time-points are included in the flow chart (Figure 7) 
Socio-demographic characteristics of HIV infected women 
The commonalities in the socio-demographic profiles of the women across all the studies 
were as follows. Most of the women had attained a formal education for at least 6 years. 
The majority were married, unemployed, predominantly Christian and Lango speaking. 
Most of the women had been pregnant for at least 4 times, including the pregnancy at the 
time of the study, with more than half having been pregnant for 20- 28 weeks at enrolment. 
Almost half of the participants reported having used an effective form of contraception 
(including oral contraceptives, intrauterine devices, injectable contraceptives or implants) 6 
months prior to the pregnancy at baseline. A considerable proportion of these women had 
disclosed their HIV status and most had disclosed this to their spouse. The majority of these 
women were taking an efavirenz-based regimen, which is also a first-line regimen. The 
majority had a viral load <50 copies/ml of blood. 
Paper I 
Prevalence and predictors of unintended pregnancy 
The participants had a mean age of 29.2 (SD 5.5). Of the 518 women enrolled on the study, 
213 experienced (41.1%, 95%CI: 36.8% - 45.5%) unintended pregnancy. 
HIV infected women who were single were almost 4 times as likely to experience 
unintended pregnancy as their married counterparts (adjusted odds ratio (AOR) = 3.74, 95% 
CI: 1.67 – 8.34). Women who had a higher parity were 3 times as likely to experience 
unintended pregnancy as those with lower number or order of pregnancies (parity of ≥5; 




AOR= 2.79, 95% CI: 1.85 – 4.22). Those who had taken ART for 10 years (120 months) or 
more were almost 4 times as likely to report that their pregnancy at the time was unintended 
than those that had taken ART for >6 months (≥120 months; AOR=3.69 (1.57 – 8.67)  
Paper II 
We included 420 women in the analysis for paper II, with a mean age of 30.0 (SD 5.2).  
Virologic profiles of HIV infected pregnant women in Lira 
The majority of the participants had an undetectable viral load. The prevalence of a 
detectable viral load (>50 copies/ml) was 30.7% (95%CI: 26.3 - 35.4%). Of those with a 
detectable viral load, the majority (82/420, 19.5% 95%CI: 15.8 – 23.6%) had a viral load 
between 50 and 400 cps/ml. The proportion of women with a viral load ≥1000 cps/ml was 









<50  291  69.3   Undetectable VL  
 69.3% (95% CI: 64.6 ‐ 74.7%) 
50 to 400  82  19.5   Detectable VL 




Factors associated with detectable viral load 
Belonging to ethnic groups other than Lango was associated with having detectable viral 
load among HIV infected pregnant women (AOR = 1.92, 95% CI: 1.05 – 3.90). Women 
who were taking a protease inhibitor-based regimen which is also a second-line treatment 
were 4 times more likely to have detectable viral load as those who had been taking a first-
line efavirenz-based regimen (AOR=4.41 95% CI: 1.13 – 17.22). 
 
 





There were 472 women in this analysis. The mean age for the HIV-positive pregnant 
women at baseline was 29.4 years (SD 5.4). The majority had a spontaneous vaginal 
delivery in a hospital setting, were given nevirapine syrup by the health worker, and were 
adherent to their ART.  
Non-adherence to infant nevirapine prophylaxis among infants at 6 weeks 
A total of 70 infants (14.8%, 95%CI: 11.7 - 18.4%) missed between 3 and 7 doses in the 
week preceding the interview and were considered non-adherent. 
Barriers and enablers of adherence to infant nevirapine prophylaxis  
Barriers to adherence to infant nevirapine prophylaxis were the following maternal 
characteristics: younger age (≤20 years ARR=1.55; 95% CI: 1.1 – 2.2), having missed a 
viral load test during pregnancy (missing viral load ARR: 1.4; 95% CI: 1.1 – 1.7), and not 
receiving nevirapine syrup for the baby after childbirth (ARR = 6.2; 95% CI: 5.1 – 7.6). 
Maternal characteristics that enabled infant nevirapine adherence include: having attained 
≥14 or more years of schooling (ARR = 0.7; 95% CI: 0.5 – 0.9), taking a nevirapine-based 
regimen (ARR = 0.6; 95% CI: 0.4 – 0.9), having taken ART for a longer period of time 
(long-term (≥ 60 months) ARR = 0.75; 95% CI: 0.6 – 0.9), accompanied by her husband to 
hospital during labour and childbirth (husband ARR = 0.5; 95% CI: 0.4 – 0.7), and having 
labour start during the night (ARR = 0.7; 95% CI: 0.6 – 0.8) (Table 3). 
Paper IV 
We included 466 HIV infected women with a mean age of 29.5 years (SD 5.4) in this 
analysis. Most of the mothers went into labour during the daytime and had spontaneous 
vaginal delivery. Three quarters delivered in a hospital setting, with most being supervised 
by a health worker. Almost a third did not adhere to their antiretroviral treatment in the 
week preceding delivery. Thirty percent of infants did not adhere to their nevirapine 
prophylaxis at 6 weeks of age.  
Infant feeding practices at delivery, 6 and 14 weeks postpartum 
The proportion of infants that were exclusively breastfed reduced with increasing age of the 
infant. Incidence of pre-lacteal feeding at birth was 12.7% (95%; CI: 9.8 - 16%). The 




incidence of non-exclusivity of breastfeeding at 6 weeks and 14 weeks postpartum were 
22.5% (95%; CI: 18.8 - 26.6%) and 42.9% (95%; CI: 38.3 - 47.5%), respectively. By the 
time the infants were 14 weeks of age, almost half were not exclusively breastfeeding. The 











   n  %  n  % 
Only breast milk  361  77.5  266  57.1 
Honey  55  11.8  44  9.4 
Water  23  4.9  36  7.7 
Cow's milk  13  2.8  70  15 
Soup  6  1.3  17  3.7 










Risk factors for non-exclusivity of breast feeding at 14 weeks of age 
Women who were in the topmost socio-economic strata were almost 45% more likely to 
give their infants liquids other than breast milk compared to those in the lowest socio-
economic strata (ARR = 1.45, 95%; CI: 1.01 – 2.09). Women whose delivery was 
supervised by a non-health worker were 64% more likely to practice mixed feeding 
compared to those whose delivery had been supervised by a health worker (ARR=1.64, 
95%; CI: 1.01 – 2.72). Women who had not adhered to their ART during pregnancy were 
also likely to practice mixed feeding for their infants compared to their adherent 
counterparts (ARR=1.29, 95%; CI: 1.01 – 1.74). 
 














































Discussion of the findings 
In this thesis, a group of HIV-infected pregnant women in Northern Uganda were studied; 
in brief we found that this group had high prevalence or incidence of unintended 
pregnancies, detectable viral load, non-adherence to infant nevirapine prophylaxis and non-
exclusive breastfeeding.  
Proportion of and predictors for unintended pregnancy among HIV infected women 
Prevalence of unintended pregnancy  
Among HIV-infected pregnant women who were receiving antenatal care at Lira Regional 
Referral Hospital (LRRH), the prevalence of unintended pregnancy was >40%. This high 
level could be attributed to an unmet need for family planning. Generally, studies that report 
high rates of unintended pregnancy also report high rates of an unmet need of family 
planning (26,31,33,38,92–94), as in our study. Several studies have reported a high rate of 
unintended pregnancy ranging from 35 to 78% (16,24,31,33,38,39,49,93,95). Studies in 
Nigeria and Zimbabwe indicate lower rates of unintended pregnancy than our study (24,39). 
Other studies have reported higher rates of unintended pregnancy than our study 
(31,33,36,38,48,49,51,93,95), but they are not directly comparable. This might be due to 
several differences in methodology: first, the way unintended pregnancy was measured; 
several studies did not rely on the definitions of unintended pregnancy stipulated in the 
London Measure of Unintended Pregnancy (LMUP), as in our study. Second, the timing of 
asking about unintended pregnancy differs between studies. Most of the studies asked about 
the intention of the pregnancy long after the women had given birth, not while they were 
pregnant as in our study.  
Predictors for unintended pregnancy among HIV infected pregnant women 
HIV infected women who were single were more likely to experience unintended 
pregnancy. A plausible explanation for this is that, in a marital union, there are open 
communication channels between the 2 individuals who can discuss reproductive-related 
issues like child-bearing and the use of contraceptive. Other studies (43,44,49) have also 
documented that WLH in a relationship were more likely to use contraception if there was 
an open partner discussion in the relationship, this type of communication being absent 




when a woman has no partner. Studies in Kenya, Swaziland, Botswana and South Africa 
have reported similar results (31,36,38,49,51,95).  
Our study also showed that experiencing a higher number of pregnancies also increased the 
likelihood of experiencing unintended pregnancy among WLH. A probable explanation for 
this finding could be inconsistency in the use of contraception, lack of emergency 
contraceptives, side effects of the contraception (heavy bleeding), partner refusal, or no 
contraceptives being available at health facilities. Our findings were consistent with results 
from other studies in South Africa and Botswana (31,38,49), but different results were 
found in Cameroon and Uganda (32,85). One study in Kenya (95) showed that the odds of 
lower order pregnancies to be unintended were the same as those of higher order 
pregnancies, although the cohort in this study was adolescents, which could explain the 
difference.  
It was unexpected to note in our study that HIV infected women who had taken ART for a 
long time were more prone to an unintended pregnancy. It might be that women on long-
term ART become complacent and in so doing lack adherence to both ART and 
contraceptive use. In a study in Uganda (96), individuals who had taken ART for a long 
time hardly received any continuous ART adherence education, experienced treatment 
fatigue and were less likely to adhere to their treatment. Studies in South Africa, however, 
found that women who had been newly diagnosed with HIV were more likely to experience 
unintended pregnancy (31,49). More qualitative studies are needed in our study context to 
understand reasons for this finding. 
Detectable viral load among HIV infected pregnant women 
One third of our participants had detectable viral load while pregnant, a higher proportion 
compared to some other studies using the same cut-off of 50 copies/ml. Studies from South 
Africa and Malawi reported lower prevalences of detectable viral load among HIV infected 
pregnant women ranging from 10 to 23% (18,86,97,98). Other studies have demonstrated 
the association between detectable viral load and poor or non-adherence to ART (99–103). 
We did not measure non-adherence; despite this, non-adherence remains the most plausible 
explanation for the high prevalence of undetectable viral load. 




The cut-off used for detectable viral load will also determine its prevalence. The lower the 
cut-off, the higher the prevalence is likely to be. A study in Malawi reported a similar 
prevalence of detectable viral load like our study, whereas researchers from Rwanda 
reported a higher prevalence. These studies, however, used a lower cut-off (63,104). In our 
study the prevalence of virologic non-suppression (>1000 cps/ml) was 8%. Studies in 
Uganda and Malawi reported a similar prevalence of virologic non-suppression among HIV 
infected pregnant women (103,105). The low prevalence of virological non-suppression 
among women presenting for antenatal care in Lira can be used as an argument for the 
success of the universal treatment program in maintaining viral suppression, and of the 
progress towards the last 90% of the UNAIDS 90-90-90 target. Much as we have achieved 
the desired target for viral suppression today, the cut-off of 1000 copies/ml used in Uganda 
is too high. This puts a focus on HIV infected pregnant women with higher virologic 
profiles and less emphasis on those with lower, but detectable, HIV-1 RNA; and yet it is 
those with detectable viral load that are likely to translate into virologic non-suppression. 
Factors associated with detectable viral load among HIV infected pregnant women 
In our study, women belonging to other ethnic groups than the predominant Lango group 
had a higher probability of having a detectable viral load, which was unexpected. A study in 
Benin found the opposite, that the predominant ethnicity of the study setting was more 
likely to have a detectable viral load (61). More qualitative work is needed in our study 
context to understand reasons for this finding. 
We also found that taking a second-line protease inhibitor-based regimen increased the odds 
of having a detectable viral load, which is a quite common finding. Studies in Uganda and 
the USA found that protease inhibitor-based regimens were associated with lower 
probability of viral suppression than first-line efavirenz-based and nevirapine-based 
regimens among HIV infected pregnant women (58,106). However, there was no difference 
in the rate of viral suppression among women using protease inhibitor-based regimens and 
those using efavirenz-based or nevirapine-based regimens in the postpartum period (106–
108). This finding can also be explained by the concept of reverse causality. HIV infected 
women will be switched to a second-line ART regimen because of treatment failure of the 
first-line regimens, which is mainly due to non-adherence (69,109). It is probable that the 
underlying challenges of adherence forcing these women onto second-line regimens may be 




aggravated during the use of second-line ART regimens. Non-adherence may be influenced 
by a number of factors, which may include side effects to antiretroviral drugs, pill burden in 
the context of pregnancy, and increased psychosocial stressors related to pregnancy or care 
giving (109). 
Non-adherence to nevirapine prophylaxis among 6-week-old HIV exposed infants 
We found that non-adherence to infant nevirapine prophylaxis was high at 14.8%. We relied 
on the mother or caregiver’s report in measuring adherence of the infant to nevirapine 
prophylaxis. Studies in South Africa have reported levels of non-adherence to infant 
nevirapine prophylaxis ranging from 12 to 30%, a range within which our data on the 
incidence of non-adherence falls (21,110,111). Studies that rely on self-reported or 
caregiver’s report indicate higher levels of non-adherence compared to those that have 
relied on electronic dose monitoring and plasma concentration of therapeutic levels of 
nevirapine in the infant’s blood (21,70,110) All these studies measure adherence to infant 
nevirapine prophylaxis at different time-points, some at birth and the majority at 6 weeks, 
while factoring in variable recall periods. Even is this scenario could explain the disparities 
in rates of non-adherence across the different studies and ours, it is likely that actual 
differences in adherence rates do exist in the different study contexts. The most important 
and actionable reason for the high non-adherence to infant prophylaxis is that many women 
did not receive nevirapine for the baby after delivery.  
Barriers and enablers of adherence to infant nevirapine prophylaxis  
In the following section, we shall focus on barriers and enablers to infant nevirapine 
adherence that are important for policy. The barriers to infant adherence include younger 
maternal age, missed viral load test during pregnancy, and mothers not receiving  nevirapine 
syrup for their infants after childbirth. Enablers to adherence included an HEI being born to 
a woman who: was well-educated (≥14 years of schooling), was taking a nevirapine-based 
regimen, has been on long-term ART, had a night-time onset of labour and was attended to 
by the husband during childbirth.  
Our study showed that infants born to younger women were less likely to be adherent to 
their prophylactic treatment, a number of studies reaching a similar conclusion 
(21,109,112). Most young mothers in our cohort had taken ART for a shorter duration (<6 




months). This means that their interface with the healthcare system was limited and that 
they had not had time to receive adequate ART adherence counselling, and subsequently 
were less well informed about the necessity to adhere to treatment and prophylaxis. This is 
supported by the fact that babies born to women on long term ART in our cohort were likely 
to be more adherent to prophylaxis than those born to women on shorter duration of ART. 
This finding further demonstrates that women who have been on ART for longer periods are 
aware of the benefits of adherence to ART compared to their counterparts that have been on 
ART for a shorter period. One study also demonstrated that women who have taken ART 
for shorter periods were more likely to report side effects of ART, which affected their 
adherence to ART (113). While conducting ART adherence counselling, health workers 
need to pay special attention to these younger mothers. 
In our study, infants born to women who did not receive nevirapine syrup from the health 
worker for the baby were unlikely to adhere to infant ART prophylaxis. Many women in our 
cohort who never received nevirapine for the baby did not have a clinic delivery, mostly 
being home deliveries. Studies done in Zambia and South Africa, and a systematic review 
for sub-Saharan Africa, showed an association between home delivery and non-adherence to 
infant prophylaxis (110–112). Home deliveries have also been associated with the mother 
not receiving nevirapine syrup for the baby from the health worker at the time of delivery 
(70,112). Women delivering at home may not have been able to return to the hospital to get 
the infant’s syrup for different reasons. Women delivering outside the hospital are less 
likely to receive counselling on the importance of their baby adhering to prophylaxis, due to 
the absence of a skilled birth attendant or health worker. Furthermore, HEIs born to women 
whose labour started in the night were more likely to adhere to nevirapine prophylaxis. 
Most women in our cohort are multiparous or of higher gravidity. Progress in labour for 
multiparous women is faster (114). Women whose labour begins in the night are most likely 
to deliver during daytime, which means they will be able to receive NVP syrup for the baby 
from the health worker at the PMTCT clinic. The PMTCT clinic is usually closed in the 
evening and night in our study setting. Women without NVP cannot administer it to the 
baby, and this contributes to non-adherence of the HEI to prophylaxis (112). An alternative 
strategy would be to provide all HIV infected pregnant women with NVP syrup for the baby 
from the ANC prior to delivery. 




Infants born to women who did not have a viral load test done during pregnancy were less 
likely to adhere to the infant prophylaxis. The main reason for this was because they had 
been on ART for >6 months (10). Having had less time in healthcare, these women have not 
yet benefitted from on-going and continuous ART counselling. Women who have taken 
ART for shorter periods of time remain a critical target for adherence counselling.  
We have shown that infants born to educated mothers were more likely to adhere to their 
prophylaxis. Educated mothers more likely read and comprehend concepts of adherence 
taught during ART adherence counselling sessions, and therefore are more likely to support 
their infants with adherence to prophylaxis. Some studies have shown no association 
between maternal education and infant adherence to nevirapine prophylaxis, whereas others 
have shown an association between lack of maternal education and low infant nevirapine 
adherence, as in our study (69,70,112).  
Women who were taking an NVP-based regimen were more likely to have infants that 
adhere to infant prophylaxis. In our cohort, women taking NVP-based regimens have taken 
ART for longer periods of time, benefits that have been discussed above. 
Women accompanied to the hospital by their husbands for labour and delivery were more 
likely to have infants that were adherent to their prophylaxis. The husband plays a key role 
in decision making when it comes to newborn care (115). Male involvement in PMTCT 
generally improves adherence to the whole PMTCT programme. Other studies have actually 
demonstrated that male involvement in maternal and child health services promotes 
adherence to infant nevirapine prophylaxis (112,116). This finding evidently shows that if 
PMTCT programs in our study context and those similar to it promoted male involvement, 
this would not only enhance adherence to infant prophylaxis, but to the entire PMTCT 
cascade of interventions. 
Exclusive breastfeeding among 14-week-old HIV exposed infants 
The proportion of infants that were exclusively breastfed reduced with increasing age of the 
infant; by 14 weeks of age, almost half were not exclusively breastfed. We found a low 
proportion of EBF of 57% among 14-week-old HEIs, probably because their mothers 
perceived that their breast milk was insufficient and that it would not satisfy the baby; 
therefore they resort to other feeding options for the infant, such as cow’s milk, water and 




porridge (89). Cultural beliefs surrounding breastfeeding also influence infant feeding 
practices, for example, believing that giving honey to the baby will protect them against 
false teeth and colic pain (115). Giving the baby prelacteal feeds also contributed to non-
EBF. Studies from South Africa and Nigeria report a similar trend in exclusive 
breastfeeding among HIV exposed infants as they grew older (77,79). Some systematic 
reviews and observational studies have reported rates similar to those in our study 
(74,75,78,80). However, one study from Tanzania reported a higher prevalence of exclusive 
breastfeeding than our study (117). These disparities could be explained by the fact that they 
included infants of varying ages and were done in different socio-cultural contexts. 
However, we cannot dispute the fact that actual differences are most likely to exist.  
It was common for mothers to give their infants prelacteal feeds after delivery. Women are 
most likely to give their babies prelacteal feeds because of sore breasts, perceived 
insufficient milk flow immediately after delivery, social and cultural issues, such discarding 
colostrum (89). Several studies of HEI infants demonstrate that mothers give infants these 
feeds due to insufficient breast milk shortly after delivery, because of breast problems or 
maternal death (78). One study from Northern Uganda, a context similar to our own, 
showed that lactating women discard colostrum shortly after delivery because they 
culturally perceive it to be dirty and harmful to the baby (89). This could possibly explain 
why infants in our cohort were given prelacteal feeds. An infant not receiving colostrum 
misses out on the essential benefits, i.e. building up the immune system and lining of the 
infant’s gut to keep pathogens at bay. This is a potential risk for mother-to-child 
transmission of HIV and development of opportunistic infections.  
 
Risk factors for non-exclusivity of breastfeeding 
In our cohort, women of the highest socio-economic status were more likely not to 
exclusively breastfeed their infants compared to those in the lowest socio-economic strata. 
One study demonstrated an association between socio-economic status and exclusive 
breastfeeding (118). Most women in the topmost socio-economic strata in our cohort were 
actually employed and probably had to return to work shortly after delivery because of 
work-related demands and pressures.  




Women whose delivery was supervised by a non-health worker were less likely to 
exclusively breastfeed and were likely to have had a home delivery. Having a home delivery 
deprives the mother of interacting with a health worker and a healthcare setting, thereby 
losing out on the benefits of counselling and support for exclusive breastfeeding. Some 
systematic reviews and observational studies showed that women who attended antenatal 
care clinics, those that delivered in a hospital and had infant adherence counselling, were 
more likely to practice exclusive breastfeeding (74,75,78,80,89,119). In a hospital setting, 
there is on-going infant feeding training for the healthcare worker and infant feeding 
counselling for the mother. Another study from Northern Uganda found that health workers 
were key decision-makers when it came to breastfeeding (115). These findings from various 
studies clearly explain why a mother whose delivery is not supervised by a health worker is 
most unlikely to exclusively breastfeed her infant. In light of this, it is important that infant 
feeding counselling is introduced in a combination of settings, and not just at health 
facilities, e.g. at the facility, workplace, community and home settings. 
Our study demonstrated that women not adhering to ART during pregnancy were also 
unlikely to exclusively breastfeed their infants. Being non-adherent to ART can be a 
consequence of a low degree of interaction with the healthcare system (120). Therefore, 
these women will not achieve the benefits of this routine interaction with the healthcare 
system, e.g. continued counselling on infant feeding. Hence women who are non-adherent 
to ART will most unlikely be adherent to infant feeding guidelines, and will not exclusively 
breastfeed their infants. Non-adherence to ART will lead to higher viral loads and advanced 
HIV disease, which poses a high risk for transmission of HIV from a mother to her baby 
during breastfeeding. Few studies have examined antiretroviral adherence during pregnancy 
and its association with infant feeding practices. However, pregnancy in itself has been 
associated with low ART adherence (121). Drug-related factors, such as side effects and pill 
burden, as well as physiological changes during pregnancy, are barriers to ART adherence 
(122). Further qualitative studies should be done to shed more light on the association 
between ART adherence and breastfeeding. 
This study generated key context-specific factors contributing to the increased risk of 
mother-to-child transmission of HIV in this resource-limited setting with its high burden of 




antenatal HIV infection of 13.5%. These findings may form the basis for targeted 
interventions.  
  




Discussion of the methods 
Strengths and limitations of the methods and design 
We have summarised the methodological strengths and weaknesses of the different sub-
studies in Table 5.  
In papers I and II, we employed a cross-sectional design. This design gave us the 
opportunity to collect information on various exposure and outcome variables in a 
reasonable period of time in order to measure prevalence and predictors of unintended 
pregnancy and detectable viral load in our study context.  
We collected data for paper I and II at one time-point and were able to assess 2 outcomes. 
This was an inexpensive way of achieving our objective. The risk of loss to follow-up was 
minimized, since participants were not followed up after the initial encounter. However, 
some potential participants declined to participate in the survey at the beginning of the 
observation, mainly due to their spouses declining (Figure 7). Our survey included pregnant 
women most of whom were in a marital union or cohabiting. After given consent prior to 
participation in the study, most women reported that they had to first consult with their 
spouses for approval before participating in the study. However, some of the pregnant 
women’s spouses had them decline participating, referring to it as a waste of time. This 
introduced some form of non-response bias. However, the study team took an extra step of 
sending an information sheet to the spouse through the participant, as well as making 
telephone calls to explain any questions that might have been unclear or caused anxiety. 
We could not fully decide whether the established exposures in papers I and II preceded the 
outcomes of unintended pregnancy and detectable viral load, respectively. For this reason 
we could only establish associations, but not the causal relationship, between the exposures 
and these outcomes.   
In paper I, we asked the women about pregnancy intent at 20 weeks of gestation or more. 
By this time, a woman might have already come to terms with an originally undesired 
pregnancy. Our results may therefore be some kind of ‘under-estimation’ of unintended 
pregnancies in this group. Furthermore, women with unintended pregnancy are more likely 
to seek abortion prior to 20 weeks of gestation. Since these women were not eligible to 
participate, it is possible that our estimation for the prevalence for unintended pregnancy 




was lower than it would have been if we had asked them at an earlier time-point. On the 
other hand, we used a validated instrument in measuring pregnancy intent, which is a 
strength. We also measured pregnancy intention with regard to the index pregnancy while 
the women were pregnant. However, we did not classify unintended pregnancy into its 
subsets – untimed, unwanted or unplanned. It was difficult to make comparisons between 
our study and other evidence that had these classifications. However, these studies were 
very few.   
Most studies on unintended pregnancy have investigated the general population and very 
few WLH. Some predictors for unintended pregnancy are unique to WLH, e.g. issues 
surrounding ART and viral loads. Therefore, it was a challenge to compare the findings 
from paper I with data on the general population. 
In paper II, we did not report any adherence rates at the point of measuring detectable viral 
load. We could not rely on the adherence rates that were recorded on the participant’s 
hospital record at enrolment/baseline. This information was inaccurately documented. More 
than half of the participants’ hospital records lacked information on adherence assessment 
and scoring. We therefore dropped this variable during the analyses in paper II. However, 
we measured maternal ART adherence at the time of delivery, factoring in a 7-day recall.  
We used a prospective cohort design in papers III and IV, and were able to follow one 
cohort of HIV infected women and study both the outcomes of adherence to infant 
prophylaxis and exclusive breastfeeding, for which we directly calculated incidence and 
relative risks. We followed up these participants at specified time intervals, at which points 
we measured the outcomes, employing a 7-day recall. This might have limited the 
possibility of recall bias. 
It was clear for papers III and IV that the established exposures at the beginning of the 
observation preceded the outcomes of adherence to infant prophylaxis and exclusive 
breastfeeding; therefore there was clarity in the temporal sequence between the independent 
and dependent variables. Since the outcomes in papers III and IV were unknown when the 
exposure status was being established at the beginning of the observation, selection bias was 
unlikely. 




The prospective cohort design enabled us to monitor the trends in exclusive breastfeeding in 
paper IV, as well as various infant feeding practices at birth, 6 weeks and 14 weeks. We 
found that the rate of exclusive breastfeeding among HIV exposed infants decreased with 
increase in the infants’ age. 
The prospective cohort study design was quite expensive and required a lot of time because 
we had to follow up this cohort at various time-points in order to reach the different 
outcomes of interest. Several participants that had been enrolled onto the study dropped off 
for various reasons (Figure 7), which caused loss to follow-up along the cascade. However, 
for purposes of follow-up we relied a lot on a functional telephone contact that the 
participant availed to the study team at baseline recruitment. 
In paper III, we relied on the mother’s or caregiver’s report for measuring infants’ 
adherence to nevirapine prophylaxis. Measuring medication adherence, while relying on 
self-reporting, is influenced by the period of recall. Our adherence estimates were likely to 
be overestimated due to the recall bias and social desirability inherent in self-reporting 
(110,114). However, other studies have demonstrated correspondence between relying on 
self-reports and other measures of adherence (21,123). The definitions of adherence 
adopted, the methods used to measure it, and the recall periods varied across different 
studies, making comparisons difficult.  
In Paper IV, we measured exclusive breastfeeding at 6 and 14 weeks using a 7-day recall of 
the mother or care giver. It is well-known that infant feeding recalls are prone to bias. A 7-
day recall is a “middle way” between 24-h recall which may be more accurate, but may not 
take into account all the feeds offered to the infant and “ever-recall,” which may have even 
more recall bias.  
All sub-studies were conducted in a hospital setting that is public in nature, a rural context, 
and among women attending and receiving antenatal care at LRRH. Therefore, findings for 
all outcomes in the studies in this thesis may only be generalizable to WLH from within this 
study context and those similar to it.  
Our study on detectable viral load is the first to describe virologic profiles among HIV 
infected pregnant women in Northern Uganda, and demonstrates that actually disparities in 
viral suppression exist in this study setting. Most studies that have been conducted on 




adherence to infant nevirapine prophylaxis are qualitative in nature. We measured exclusive 
breastfeeding continuously from birth till 14 weeks postpartum and relied on a 7-day recall, 
which helped to avoid exaggerating the incidence of exclusive breastfeeding in our cohort. 
We managed to create a cohort cascade that mimicked an actual PMTCT programmatic 
cascade and to retain 90% of the participants until the end. 
The principal investigator was not an employee of the hospital in which these studies were 
conducted. Much as this could have been advantageous, but it could have had its 
disadvantages. Being an employee of LRRH would have compromised the candidate’s 
position as a researcher in that she might not judge properly some study limitations; for 
example, it would be rather difficult to disclose that LRRH hospital records were 
problematic and incomplete. Even when the principal investigator could not speak Lango, 
the team that was recruited to enrol and follow up participants had to be fluent in the 
language predominant in the study context. 
Another strength of our studies is the high completion rate of 90% along our cohort cascade 
(Figure 7). To minimize loss to follow-up, we documented the telephone contacts and 
residential mapping of each participant. A home visit was made when we could not reach 
the participant by phone.  
A number of factors can affect the validity of a study, in particular in similar studies where 
the main data collection is through interviews. The 2 most commonly discussed are recall 
bias, where the person interviewed does not recollect (or correctly recall) events in the past, 
and social desirability bias, where the person consciously or unconsciously modifies his/her 
answers to be more socially acceptable (124). 
 
  














































































HIV infected women in Northern Uganda were at higher risk of infecting their infants with 
HIV if they are: younger, not in a marital union, non-native to Lira, non-adherent to ART or 
had recently started on ART (those who miss having viral load tested during pregnancy), or 
had delivered outside the hospital (those whose births were unsupervised by a health worker 
and did not receive nevirapine syrup for their infant after childbirth). Special attention is 
needed regarding these critical groups during the implementation of PMTCT programs in 
Lira, Northern Uganda and similar contexts. 
Recommendations for policy 
We recommend that WLH with detectable viral loads be included in the category that is 
eligible for intensive adherence counselling, like those that are unable to achieve viral 
suppression. This is because WLH with detectable viral loads are more likely to develop 
resistance to and failure of the first-line regimen. Counselling also needs to be focused on 
groups of WLH found to be at risk of infecting their babies with HIV. This includes women 
who: are younger, not in a marital union, non-native to Lira, non-adherent to ART, had 
recently started on ART (those who miss having viral load done during pregnancy), or had 
delivered outside the hospital (those whose births are unsupervised by a health worker and 
do not receive nevirapine syrup for their infant after childbirth). 
We recommend intensified clinical and psychosocial monitoring of medication compliance 
among HIV infected pregnant women who may have a detectable viral load to significantly 
lower the risk of vertical transmission of HIV. This is specifically valid for those taking a 
protease inhibitor-based regimen and who are non-natives to the study setting. 
The health system needs to consider giving the infant nevirapine syrup to HIV infected 
pregnant women before birth to avoid delays and non-adherence. There is also a need to pay 
particular attention to younger women and those who recently started ART. We recommend 
ART adherence and infant feeding counselling to be emphasized and integrated in diverse 
settings, such as homes, workplaces, communities and health facilities. 
  




Recommendations for future research 
We recommend further qualitative investigation into the fact that disparities in viral 
suppression occur in this study context. We also recommend that the protective effect of 
night-time onset of labour against home delivery and non-adherence to infant nevirapine 
prophylaxis could be investigated in this setting. 
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Was: Detectable viral 
load 
HIV infected pregnant woman on ART having a viral 
load count between 50 and 999 copies per ml blood 
Is now: Detectable viral 
load 
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prevalence and predictors 
for unintended pregnancy 
among HiV‑infected pregnant 
women in Lira, northern Uganda: 
a cross‑sectional study
Agnes napyo 1,2,4*, Victoria nankabirwa3,4, David Mukunya4, Josephine tumuhamye4, 
Grace ndeezi2, Anna Agnes ojok Arach2,5, Beatrice odongkara2,4,6, paul Waako7, 
thorkild tylleskär4 & James K. tumwine2
prevention of unintended pregnancies is a global strategy to eliminate mother‑to‑child transmission 
of HiV. factors surrounding unintended pregnancy among women living with HiV are not well 
understood. We aimed to determine the prevalence and predictors for unintended pregnancy among 
these women in Northern Uganda. We conducted a cross-sectional survey among 518 women using a 
structured questionnaire. We asked questions on socio‑demographic, reproductive‑related and HiV‑
related characteristics. We conducted multivariable logistic regression and reported adjusted odds 
ratios. The prevalence of unintended pregnancy was 41.1%. The predictors for unintended pregnancy 
were: being single (not living with a partner or being in a marital union), having five or more children 
and taking antiretroviral drugs for long periods of time. HiV counselling services should target women 
living with HiV who are not in a marital union, those having a higher parity and those who have taken 
ARt for longer periods.
The Human Immunodeficiency Virus (HIV) prevalence in Uganda was 6.0% in  20171. There has been a scale 
up of prevention of mother-to-child transmission of HIV-1 (PMTCT) services covering over 95% of pregnant 
women and as a result there has been a significant reduction in the mother-to-child transmission of HIV-1 
(MTCT) rate to less than 5%1. The global strategy by the World Health Organisation (WHO) for PMTCT is multi-
pronged and includes: (a) primary prevention of HIV infection among women of child-bearing age, (b) preven-
tion of unwanted pregnancies among women living with HIV (WLH), (c) prevention of HIV transmission from 
WLH to their infants and (d) provision of appropriate treatment to WLH and their  children2. Uganda has taken 
strides in PMTCT largely because of infections prevented due to the provision of antiretroviral therapy (ART) 
to pregnant WLH; these strides do not reflect infections averted due to preventing unintended  pregnancies1. 
Fertility desires for WLH have increased  overtime3–7 and so it is eminent to support them in their fertility choices 
through family planning and contraception. To ensure provision of contraception, the consolidated guidelines 
for prevention and treatment of HIV in Uganda promote the availability of accessible and comprehensive con-
traceptive services for WLH to not only meet their birth control needs but to also reduce rates of unintended 
 pregnancy2. Prevention of unintended pregnancy through reliable contraceptive methods reduces MTCTof HIV, 
improves women’s health as well as reduce both maternal and infant mortality among WLH and their  offspring6. 
Preventing unintended pregnancy also offers several additional benefits for WLH and their babies by reducing 
open
1Department of Public Health, Faculty of Health Sciences, Busitema University, Mbale, Uganda. 2Department 
of Paediatrics and Child Health, College of Health Sciences, Makerere University, Kampala, Uganda. 3School 
of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda. 4Centre for International 
Health, University of Bergen, Bergen, Norway. 5Department of Nursing and Midwifery, Lira University, 
Lira, Uganda. 6Department of Paediatrics and Child Health, Gulu University, Gulu, Uganda. 7Department of 
Pharmacology, Faculty of Health Sciences, Busitema University, Mbale, Uganda. *email: napyoagnes@gmail.com
2
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:16319  | https://doi.org/10.1038/s41598-020-73490-6
www.nature.com/scientificreports/
the number of infants who acquire HIV and consequently those who need HIV services as well as increased 
survival for HIV exposed  infants2.
Conversely, unintended pregnancy poses health consequences for mothers, their babies and  families8,9. 
A woman who conceives and gets pregnant when she does not desire to will not to seek prenatal care early 
 enough8,10. A baby born to a mother who did not desire her pregnancy is likely to have low birth weight and other 
life threatening  issues11. Both parents to the baby may suffer economic  hardship11. Most importantly, WLH that 
experience unintended pregnancy are more likely not to adhere to the ART and hence frequently have elevated 
viral load  counts12,13. Such grave consequences undoubtedly increase the risk of MTCT of HIV.
Much as integration of family planning into HIV services exists, the rates of unmet need for contraception 
remain  elevated6 ranging from 36 to 75%14–20 which results into high rates of unintended  pregnancy19,21 in sub-
Saharan Africa that range from 35 to 71%3,7,13,17,19,20,22–27. Unintended pregnancy can also result from incorrect or 
inconsistent use of  contraception5,24, interaction of hormonal methods with ART making them less  effective28,29, 
miscalculation of safe days while relying on non-modern  contraception19,30 and contraceptive  failure7,20.
Existing evidence demonstrates that various factors have been associated with unintended pregnancy among 
WLH and these are younger age, being single, ethnicity, education status, higher parity, having had a previous 
abortion, late or no antenatal care attendance, incorrect or inconsistent use of barrier methods, elevated viral 
load, peri-partum CD4+ immune suppression and long term ART  use5,12,13,22–24,30–32.
Studies that have been done on this subject matter have mainly looked into predictors for contraceptive 
use in the context of HIV and only, in a few cases, mentioned the rates of unintended pregnancy but rarely, 
its predictors. Furthermore, the unmet need for contraception is higher among WLH than their HIV negative 
 counterparts21 translating into WLH facing higher rates of unintended pregnancy than their HIV negative 
 counterparts31. Factors surrounding unintended pregnancy among WLH in Uganda are still not well understood 
yet they remain a public health challenge. We therefore aimed to determine the prevalence and predictors for 
unintended pregnancy among HIV infected pregnant women in Lira, Northern Uganda.
Methods
Study design. We conducted a cross-sectional study among HIV infected pregnant women between August 
2018 and July, 2019. The exposures of interest were potential predictors which included socio-demographic, 
reproductive-related and HIV-related factors. The outcome of interest was unintended pregnancy.
Sample size estimation. We calculated a sample size for detecting a difference between two independent 
proportions using Stata version 14.0 (StataCorp; College Station, TX, USA). We utilized the statistics, power 
and sample-size functions. Using the population parameter method with the test of comparing two independ-
ent means (0.576 vs. 0.315), we assumed 80% power, 95% confidence interval (CI) and 5% precision. We also 
assumed that 57.6% of WLH were not in a marital  union33 and that 31.5% of HIV infected women were  married24. 
On running this calculation in the statistical software, we arrived at a sample size of 464. We adjusted the sample 
size to 516 after accounting for a 10% non-response. We however, included 518 HIV positive pregnant women 
who were receiving antenatal care at Lira Regional Referral Hospital (LRRH).
Setting. LRRH serves all the 8 districts of the Lango subregion in Northern Uganda. It is a government-
owned health facility at tertiary level that offers health services including maternal and child health services like 
HIV care, antenatal care and delivery. These services are at no cost to the patients.
LRRH also has an annual outpatient attendance of almost 100,000 patients, annual antenatal care attendance 
of about 5,000 women and conducts approximately 6–7,000 deliveries annually.
participants. HIV infected women were identified, consented and recruited consecutively through the 
existing Ugandan HIV treatment, care and support program for pregnant women at the PMTCT clinic located 
within LRRH. Women were eligible for participation if they were: 20 weeks pregnant or more, newly tested for 
HIV or already established in ART care. Those who were severely ill at the time of recruitment were excluded 
from the study and referred to appropriate care services.
Surveys and measures. The interviews were conducted in Lango (the main language spoken in the study 
setting) or English by trained study staff. Interviews consisted of socio-demographic related, reproductive-
related and HIV-related information. All measures were translated into Lango and back-translated into English 
to ensure accuracy and minimise interpretation bias. All procedures of the study were performed in accordance 
with the guidelines and regulations pertaining to all relevant approving bodies.
Unintended pregnancy, the main outcome of the study, was defined in any of the following ways: a pregnancy 
that occurred when no more children were desired or one that occurred earlier than it was desired or one that 
occurred when the woman did not desire to become pregnant. We adapted questions from the London Meas-
ure of Unplanned Pregnancy, a psychometrically validated measure of the degree of intention of a current or 
recent pregnancy. Women were asked if the pregnancy came ‘earlier than expected’, ‘later than expected’, ‘when 
expected’ or ‘not desired at all’. Women who had their pregnancy at the ‘time desired’ or ‘later than expected’ were 
combined, labelled as the ‘intended’ category and coded 0. Women with an ‘earlier than desired’ or ‘unwanted 
pregnancy’ were combined into a single group, labelled “unintended pregnancy” and coded 1. Contraceptive 
use, was defined as any contraceptive method used in the 6 months preceding the pregnancy at the time. Unmet 
need for contraception was defined as those women who experienced unintended pregnancy and did not use 
any form of contraception 6 months prior to the pregnancy. Marital status was categorised into married and 
single. Those who were married or cohabiting were combined into one group, labelled “married” and coded 1. 
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Those who were separated, divorced, widowed or not married were combined into one group, labelled “single” 
and coded 2. Women who had been pregnant for four or less times including miscarriages, abortions and the 
pregnancy at the time of the interview were collectively categorised and coded 1 for the variable “parity”, else 
were coded 2. Duration on treatment was categorised as “< 6 months”, “7–30 months”, “31–119 months” and 
“≥ 120 months”. Duration on ART of ≥ 120 months (10 years) was referred to as long-term ART  use34,35 for 
comparability purposes.
We created a composite index of wealth (socio-economic status) using principle component analysis (PCA). 
Because the PCA technique allows combination and ranking of a number of variables into smaller and fewer 
variables without prejudgment, it is considered a more accurate indicator of socioeconomic status than single 
items such as occupation or possession of particular  items36. We used PCA on house ownership, availability of 
electricity in the house, source of drinking water and fuel used for cooking. Scores were obtained and categorized 
into four groups (quartiles) ranging from the poorest to the least poor.
Data management and statistical analyses. Data were entered into EpiData software (www.epida 
ta.dk, version 4.4.3.1) by two independent data entrants and exported for analysis into Stata version 14.0 (Stata-
Corp, College Station, Texas, U.S.A.). Continuous data, if normally distributed, was summarised into means 
and standard deviations and if skewed, was summarised into medians with their corresponding interquar-
tile ranges. Categorical variables were summarised into frequencies and percentages. The proportion of HIV 
infected women with unintended pregnancies was estimated and its confidence limits calculated using the exact 
method. We used multivariable generalized linear model regression analysis with a logit link to estimate the 
adjusted odds ratios of the independent variables on unintended pregnancy while controlling for confounding. 
All variables with p < 0.25 at the bivariate level were included in the initial model at the multivariate analysis. All 
variables with p < 0.1 and those of biological or epidemiologic plausibility (from previous studies) were included 
in the second model. We checked for confounding by calculating the percentage change in each effect measure 
by removing or introducing one variable at a time into the second model. If a variable caused more than 10% 
change in any effect measure, then it was considered a confounder. Using the Likelihood-ratio test, we found that 
the first and second models were not significantly different. Therefore we adopted the second model as our final 
model. We used the visual inspection factor to check for collinearity among all the variables that were included 
in the initial model.
ethical considerations. Approval to conduct the study was granted by the Makerere University School of 
Medicine Research and Ethics Committee, the Norwegian Regional Committee for Medical and Health Research 
Ethics in the West, and the Uganda National Council for Science and Technology. Meetings were held with the 
Lira district health officer and LRRH director to grant administrative clearance to conduct the study. Additional 
meetings were held with the counsellors who work within the PMTCT clinic to introduce to them the study and 
its procedures and to request them to identify, mobilise and link willing participants with the research team. All 
participants provided written informed consent confirming their voluntary participation in the study. Those that 
declined participation were not penalised or denied standard health care. Confidentiality and privacy of all data 
collected was observed during the course of the study through restricted access.
Results
A total of 547 HIV infected pregnant women were screened for eligibility from the antenatal care clinic at Lira 
Regional Referral Hospital (LRRH) (Fig. 1). A total of 518 women participated in the study. Women did not 
participate in the study if their partner declined their participation, if they received ART care from another 
facility other than LRRH or if they were committed elsewhere. The participants had a mean age of 29.2 (SD 5.5). 
Two hundred and fifty (48.3%) had attained a formal education for a duration of at least seven years or more. 
The majority of the women were married (or cohabiting) and not formally employed. They were predominantly 
Christian and Lango speaking (Table 1). Most of the women had been pregnant for at least four times including 
the pregnancy at the time of the study with more than half having a pregnancy ranging from 20 to 28 weeks of 
gestation. A considerable proportion of these women had disclosed their HIV status and most had disclosed 
to their spouse. Almost half of the participants reported having used an effective form of contraception (oral 
contraceptives, intrauterine devices, injectable contraceptives or implants) six months prior to the pregnancy 
at the time of the study (Table 2).
predictors for unintended pregnancy. Being single was a significant predictor for unintended preg-
nancy among HIV infected pregnant women. HIV infected women who were single were almost four times as 
likely to experience unintended pregnancy as their married counterparts (adjusted odds ratio (AOR) = 3.74, 95% 
CI: 1.67–8.34). Women who had a higher parity were three times as likely to experience unintended pregnancy 
as those with lower number or order of pregnancies (parity of ≥ 5; AOR = 2.79, 95% CI: 1.85–4.22). Those who 
had taken ART for 10 years (120 months) or more were almost four times as likely to report that the pregnancy 
at the time was unintended as those that had taken ART for less than 6 months (≥ 120 months; AOR = 3.69 
(1.57–8.67) (Table 3).
Discussion
In this study we sought to determine the prevalence of unintended pregnancy and its predictors among WLH. 
The predictors for unintended pregnancy in our study were being single, having five or more pregnancies and 
taking ART for longer durations of time. In this setting we have documented a prevalence of unintended preg-
nancy of more than 40%. This high rate found in our study is probably due to the unmet need of family planning. 
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Figure 1.  Flow diagram illustrating rationale for screening, enrolment and non-enrolment.
Table 1.  Baseline demographic characteristics of HIV infected pregnant women receiving antenatal care at 
Lira Regional Referral Hospital.
Characteristics
Total Pregnancy intended Pregnancy not intended
(N = 518) (N = 305) (N = 213)
n (%) n (%) n (%)
Socio-demographic
Age
 ≤ 20 years 35 (6.8) 23 (7.5) 12 (5.6)
21–29 years 229(44.2) 150 (49.2) 79 (37.1)
 ≥ 30 years 254 (49.0) 132 (43.3) 122 (57.3)
Education
0–6 years 268 (51.7) 143 (46.9) 125 (58.7)
7–10 years 171 (33) 105 (34.4) 66 (31)
11–13 years 51 (9.9) 35 (11.5) 16 (7.5)
≥ 14 years 28 (5.4) 22 (7.2) 6 (2.8)
Marital status
Married 484 (93.4) 295 (96.7) 189 (88.7)
Single 34 (6.6) 10 (3.3) 24 (11.3)
Employment status
Employed 207 (40) 129 (42.3) 78 (36.6)
Not employed 311 (60) 176 (57.7) 135 (63.4)
Religious affiliation
Christian 500 (96.5) 292 (95.7) 208 (97.7)
Moslem 18 (3.5) 13 (4.3) 5 (2.3)
Ethnic belonging
Langi 472 (91.1) 275 (90.2) 197 (92.5)
Other 46 (8.9) 30 (9.8) 16 (7.5)
Socioeconomic index
Group 1 (poorest) 139 (26.8) 80 (26.2) 59 (27.7)
Group 2 122 (23.6) 69 (22.6) 53 (24.9)
Group 3 170 (32.8) 96 (31.5) 74 (34.7)
Group 4 (least poor) 87 (16.8) 60 (19.7) 27 (12.7)
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Generally studies that report high prevalence of unintended pregnancy also report high rates of unmet need of 
family  planning6,13,23,24,37,38 just like in our study. Several studies have reported high prevalence of unintended 
pregnancy ranging from 35 to 78%4,7,13,20,23,24,31,38,39. Studies in  Nigeria4 and  Zimbabwe20 reported lower prevalence 
of unintended pregnancy than our study. This could be attributed to the fact that in both studies, the way the 
outcome of unintended pregnancy was measured and defined was different from ours. A number of studies did 
not rely on the definitions of unintended pregnancy stipulated in the LMUP. Studies  elsewhere12,13,22–24,30,31,38,39 
reported higher prevalence of unintended pregnancy than ours. Studies report varying rates because of the dif-
ference in the types of population from which they measure unintended pregnancy. Some studies have measured 
unintended pregnancy among  adolescents39 which creates a difference in risk factors between these studies and 
ours. The timing of asking about unintended pregnancy was different between the various studies and our study. 
Most of the studies asked about intention of the pregnancy long after the women in the cohorts had given birth 
to their babies not while they were still pregnant like in our study.
In our study, HIV infected women who were single were more likely to experience unintended pregnancy. 
A plausible explanation for this is that in a marital union there are open communication channels between the 
two individuals and this facilitates open discussion on reproductive-related issues like child-bearing and con-
traceptive use. Studies done  elsewhere15,16,31 also documented that WLH in a relationship were most likely to 
use contraception if there was open partner discussion among married couples. These communication channels 
Table 2.  Other characteristics.
Characteristics
Total Pregnancy intended Pregnancy not intended
(N = 518) (N = 305) (N = 213)
n (%) n (%) n (%)
Reproductive-related
Parity
 ≤ 4 375 (72.4) 247 (81.0) 128 (60)
 ≥ 5 143 (27.6) 58 (19.0) 85 (40)
Gestational age (in weeks)
20–27 279 (53.9) 165 (54.1) 114 (53.5)
28–35 171 (33) 102 (33.4) 69 (32.4)
 ≥ 36 68 (13.1) 30 (12.5) 30 (14.1)
Accompanied to antenatal care
Not accompanied 465 (89.8) 272 (89.2) 193 (90.6)
Accompanied on day of interview 53 (10.2) 33 (10.8) 20 (9.4)
Use of birth control
Did not use 258 (49.8) 163 (53.4) 95 (44.6)
Used 6 months prior to pregnancy 260 (50.2) 142 (46.6) 118 (55.4)
Type of contraceptive used
None or safe days 267 (51.5) 167 (54.8) 100 (47)
Effective contraception 251 (48.5) 138 (45.2) 113 (53)
HIV-related
HIV status disclosure
Disclosed 501 (96.7) 299 (98.0) 202 (94.8)
Not disclosed 17 (3.3) 6 (2.0) 11 (5.2)
Person disclosed to
Husband 398 (76.8) 244 (80.0) 154 (72.3)
Other 120 (23.2) 61 (20.0) 59 (27.7)
Fear about others’ opinion on HIV status
Had no fear 253 (48.8) 139 (45.6) 114 (53.5)
Had fear 265 (51.2) 166 (54.4) 99 (46.5)
Antiretroviral treatment
Efavirenz-based 466 (90) 279 (91.5) 187 (87.8)
Nevirapine-based 44 (8.5) 23 (7.5) 21 (9.9)
Protease inhibitor–based 8 (1.5) 3 (0.1) 5 (2.4)
Duration of antiretroviral treatment
Less than 6 months 98 (18.9) 64 (21) 34 (16)
7 to 30 months 117 (22.6) 70 (23) 47 (22)
31 to 119 months 267 (51.5) 159 (52.1) 108 (50.7)
 ≥ 120 months 36 (7) 12 (3.9) 24 (11.3)
6
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:16319  | https://doi.org/10.1038/s41598-020-73490-6
www.nature.com/scientificreports/
are absent when the woman does not have a partner. Studies in  Kenya39,  Swaziland22,  Botswana23 and South 
 Africa12,24,31, demonstrate similar results.
Our study also found that experiencing a higher number of pregnancies increased the likelihood of experienc-
ing unintended pregnancy among WLH. A probable explanation for this finding in our study could be inconsist-
ency in the use of contraception, under-utilisation of emergency contraceptives, side effects of the contraception 
like heavy bleeding, partner refusal or constant stock outs of contraceptives at health facilities. Our finding was 
consistent with results from other studies in South  Africa24,31 and  Botswana23. However, different results were 
found in  Cameroon33 and  Uganda26. One study in  Kenya39 showed that the odds of lower order pregnancies to be 
unintended were the same as those of higher order pregnancies, though the cohort in this study was adolescents 
which could explain the variation in findings between this study and ours.
It is surprising to note that in our study HIV infected women who had taken ART for long periods of time 
were more likely to experience unintended pregnancy. Probably, in our study context, women on long-term ART 
experience complacency and in so doing become non-adherent to both ART and contraceptive use. In a study 
done in  Uganda40, it was found that individuals who had taken ART for a long time hardly received continuous 
ART adherence education, experienced treatment fatigue and were less likely to adhere to their treatment. Studies 
in South  Africa24,31 however found that women who had been newly diagnosed with HIV were more likely to 
Table 3.  Predictors for unintended pregnancy among HIV infected women in Northern Uganda. The bold 







p value(95% CI) (95% CI)a (95% CI)b
Age
 ≤ 20 years 0.56 (0.27–1.18) 0.13 0.74 (0.3–1.81) 0.505 – –
21–29 years 0.57 (0.39–0.82) 0.003 0.86 (0.55–1.34) 0.501 – –
 ≥ 30 years 1 1 – –
Education status
0–6 years 1 1 – –
7–10 years 0.72 (0.49–1.06) 0.098 0.88 (0.57–1.36) 0.563 – –
11–13 years 0.52 (0.28–0.99) 0.047 0.71 (0.35–1.44) 0.345 – –
 ≥ 14 years 0.31 (0.12–0.79) 0.015 0.5 (0.18–1.37) 0.176 – –
Marital status
Married 1 1 1
Single 3.75 (1.75–8) 0.01 3.81 (1.68–8.66) 0.001 3.74 (1.67–8.34) 0.001
Employment status
Employed 1 1 – –
Not employed 1.27 (0.89–1.81) 0.195 1.13 (0.74–1.73) 0.581 – –
Parity
 ≤ 4 1 1 1
 ≥ 5 2.83 (1.9–4.2) 0.000 2.4 (1.5–3.86) 0.000 2.79 (1.85–4.22) 0.000
HIV status disclosure
Disclosed 1 1 1
Not disclosed 2.71 (0.99–7.46) 0.053 2.55 (0.84–7.76) 0.1 2.59 (0.86–7.78) 0.09
Socioeconomic status
Group 1 (poorest) 1 1 – –
Group 2 1.04 (0.64–1.70) 0.871 1.25 (0.73–2.14) 0.425 – –
Group 3 1.05 (0.66–1.64) 0.848 1.44 (0.87–2.38) 0.16 – –
Group 4 (least poor) 0.61 (0.35–1.07) 0.087 0.91 (0.48–1.73) 0.781 – –
Type of contraceptive used
None or safe days 1 1 1
Effective contraception 1.37 (0.96–1.94) 0.081 1.33 (0.9–1.96) 0.148 1.34 (0.92–1.95) 0.132
Antiretroviral treatment
Efavirenz-based 1 1 – –
Nevirapine-based 1.36 (0.73–2.53) 0.328 0.93 (0.43–1.99) 0.85 – –
Protease inhibitor-based 2.49 (0.59–10.53) 0.216 2.24 (0.4–12.41) 0.356 – –
Duration of antiretroviral treatment
0 to 6 months 1 1 1
7 to 30 months 1.26 (0.72–2.2) 0.409 1.25 (0.68–2.3) 0.482 1.29 (0.71–2.36) 0.398
31 to 119 months 1.28 (0.79–2.07) 0.318 1.15 (0.66–2.01) 0.628 1.19 (0.7–2.03) 0.517
 ≥ 120 3.76 (1.68–8.45) 0.001 3.32 (1.24–8.92) 0.017 3.69 (1.57–8.67) 0.003
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experience unintended pregnancy. More qualitative studies need to be done in our study context to understand 
reasons for this finding.
Strengths and limitations. The study was conducted in a hospital setting hence our findings may only 
be generalizable to WLH from within this study context and those similar to it. We did not classify unintended 
pregnancy into its variations—untimed, unwanted or unplanned. It was difficult to make comparisons between 
our study and the studies that made these classifications. However, these studies were very few. Women with 
unintended pregnancy are more likely to seek abortion prior to 20 weeks of gestation. Since these women were 
not eligible to participate in our study, it is possible that our prevalence estimation was lower than the actual.
Our study had its strengths too. We adapted use of a validated instrument in measuring pregnancy intent. 
We also measured pregnancy intention with regard to the index pregnancy while the women were pregnant. 
This discounts the plausibility of recall limitation. However, this does not remove the notion that at the time 
of measuring pregnancy intent in this cohort, some women might have already come to terms with their preg-
nancy. We measured pregnancy intent at 20 weeks of pregnancy or more. By this time, a woman might have 
already accepted and desired an originally undesired pregnancy. We, therefore, could have under reported on 
the prevalence of unintended pregnancy.
conclusions
WLH likely to experience unintended pregnancy included: those who were not in a marital union, those having 
a higher number of children and those who had taken ART for longer periods. We recommend that alongside 
integration of family planning services with existing HIV care, counselling services need to target WLH who 
are not living with a partner, those with high number of children and those that have been in HIV care for long 
periods of time.
Data availability
The datasets used and analysed during the current study are available from the corresponding author on reason-
able request.
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ABSTRACT
Background / Objectives: Detectable HIV viral load among HIV-infected pregnant women remains 
a public health threat. We aimed to determine factors associated with detectable viral load among 
HIV-infected pregnant women in Lira, Northern Uganda. 
Methods: We conducted a cross-sectional survey among 420 HIV-infected pregnant women attending 
Lira Regional Referral Hospital using a structured questionnaire and combined it with viral load tests 
from Uganda National Health Laboratories. We conducted multivariable logistic regression while adjusting 
for confounders to determine the factors associated with detectable viral load and we report adjusted 
odds ratios and proportion of women with viral load less than 50 copies/ml and above 1000 copies, 
respectively. 
Results: The prevalence of detectable viral load (>50 copies/ml) was 30.7% (95%CI: 26.3% - 35.4%) and 
>1000 copies/ml was 8.1% (95% CI: 5.7% – 11.1%). Factors associated with detectable viral load were not 
belonging to the Lango ethnicity (adjusted odds ratio = 1.92, 95%CI: 1.05 – 3.90) and taking a second-line 
(protease inhibitor-based) regimen (adjusted odds ratio = 4.41, 95%CI: 1.13 – 17.22). 
Conclusions and Global Health Implications: HIV-infected pregnant women likely to have detectable 
viral load included those taking a protease inhibitor-based regimen and those who were not natives of Lira. 
We recommend intensified clinical and psychosocial monitoring for medication compliance among HIV-
infected pregnant women that are likely to have a detectable viral load to significantly lower the risk of 
vertical transmission of HIV in Lira specifically those taking a protease inhibitor-based regimen and those 
who are non-natives to the study setting. Much as the third 90% of the global UNAIDS 90-90-90 target has 
been achieved, the national implementation of PMTCT guidelines should be tailored to its contextual needs.
Key words: • HIV • Women • Pregnancy • Pregnant women • Viral load • Viral suppression • PMTCT  
• Antiretroviral therapy • Uganda
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1. Background and Introduction
Worldwide, there were 37.9 million people living 
with HIV (PLH) in 2018 and about 65% had access to 
antiretroviral therapy (ART) by June 2019. 1 Eastern 
and Southern Africa bear the biggest burden of the 
epidemic1 and Uganda is no exception.2 Women are 
disproportionately affected by HIV compared to males2 
which translates into potential risk of HIV transmission 
from a mother to her offspring when getting pregnant. 
The World Health Organization as well as the Uganda 
national ART guidelines recommend combination ART 
for pregnant and breastfeeding HIV infected women 
regardless of their immune status,3,4 and the most 
common is a fixed drug combination taken once daily. 
In Uganda, more than 95% of HIV infected pregnant 
women received ART in 2017 to reduce the risk of HIV 
transmission to their offspring.2 
One of the indicators used in the prevention of 
mother-to-child transmission of HIV-1 (PMTCT) 
programs is maternal plasma HIV-1 RNA viral load.5 
Detectable or high maternal viral load increases risk 
of mother to child transmission of HIV.6 Detectable or 
high maternal viral load among HIV infected pregnant 
women has also been associated with various risk 
factors such as poor adherence to antiretroviral drugs7,8 
and type of antiretroviral regimen being ingested.9–11 
However, these risk factors vary across various study 
contexts therefore interventions targeted towards 
the virtual elimination of mother to child transmission 
of HIV in one context may not necessarily work for 
another – they may need to be context-specific.
Detectable viral load is a public health threat 
that can potentially translate into virologic failure 
and HIV drug resistance. We therefore set out to 
determine the factors associated with detectable 
viral load among HIV infected pregnant women in 
Lira, Northern Uganda. The objective of the study 
was to determine the factors associated with 
detectable viral load among HIV infected pregnant 
women in Lira, Northern Uganda.
2. Methods
2.1. Study Design
We conducted a cross-sectional study among 420 
HIV positive pregnant women on ART between 
August 2018 and July 2019. We have followed the 
STROBE guidelines in drafting of this paper.12
2.2. Setting
Lira Regional Referral Hospital (LRRH) serves all 
8 districts of the Lango sub region in Northern 
Uganda. It has an annual outpatient attendance of 
almost 100,000 patients, an annual antenatal care 
attendance of about 5,000 patients and conducts 
approximately 6,000 to 7,000 deliveries annually. 
Lira is one of the sentinel sites in Uganda with the 
highest antenatal HIV prevalence at 13.5%13 making 
it a suitable site for our study due to the availability 
of an accessible population of interest. HIV care and 
treatment at LRRH is entirely supported and offered 
freely by the Government of Uganda through the 
Ministry of Health. At the time of conducting the 
study, the Uganda national HIV care and treatment 
policy guidelines recommended that once an 
HIV-infected pregnant woman has been initiated on 
ART, viral load testing should be done six months 
after initiation of treatment and thereafter once 
every year.
2.3. Sample Size Estimation
We calculated a sample size for detecting a 
difference between two independent proportions 
using STATA version 14.0 (StataCorp; College 
Station, TX, USA). We assumed that 23% of HIV 
infected pregnant women had detectable viral 
load 14 and that 12% of HIV infected women that 
had detectable viral load were taking a protease 
inhibitor-based regimen.15 Two sample size 
calculations were done for the prevalence and 
factors associated respectively. After accounting for 
11% non-response the final sample size was 420 
(Figure 1). The sample size obtained was sufficient 
to cover the sample sizes required for estimating 
the prevalence as well as investigating the factors 
associated with detectable viral load. 
2.4. Participants
Study participants were identified, consented 
and recruited consecutively through the existing 
Ugandan program for HIV treatment, care and 
support for pregnant women at the PMTCT clinic. 
Participants were recruited onto the study as they 
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came into the clinic until the estimated sample 
size was reached. Participants included in this 
study commenced their ART at different points 
in time and only those who had been on ART for 
at least six months or more, had viral load test 
done and results available were included in the 
analysis. The Ugandan ART treatment guidelines 
recommend viral load monitoring for HIV infected 
pregnant women who have taken ART for at least 
six months.4 Participants with a viral load count 




Detectable viral load, the main outcome of the 
study, was defined as the presence of 50 or more 
copies of HIV-1 RNA per millilitre (ml) of blood 
plasma.3 Viral load counts below 50 copies/ml were 
categorized as ‘undetectable viral load’. This was 
done for comparability purposes. The presence 
of 1,000 or more copies/ml was called ‘viral 
non-suppression’. Blood was drawn from HIV-
infected pregnant women who were due for viral 
load monitoring and the blood samples shipped 
under cold chain to the Uganda National Health 
Laboratories where the viral load tests were done 
following the recommended scheduled routine as 
per the consolidated guidelines for the prevention 
and treatment of HIV in Uganda.4 The Roche cobas 
8800 system technology (Hoffmann-la roche Ltd, 
Basel, Switzerland) with a level of detection of 
40 copies/ml was used for viral load testing. The 
recommended schedule for virologic monitoring 
among HIV-infected pregnant women was having the 
viral load monitored six months after initiation of 
ART and thereafter once every 12 months. Viral load 
results were then available after two to three weeks.
2.5.2. Independent variables and covariates
The independent variables and covariates included 
in the analysis were socio-demographic-related like 
age, education, marital status, employment status, 
religious affiliation, ethnicity and socioeconomic 
index. Reproductive-related covariates included 
were: parity, gestational age, birth control use and 
intention to have baby. HIV-related covariates 
included were: HIV status disclosure, ART regimen 
and duration of ART.
Ethnicity was categorized as ‘Lango ethnicity’ or 
‘other’. Antiretroviral treatment was categorized 
as ‘efavirenz-based’, ‘nevirapine-based’ or ‘protease 
inhibitor-based’. The latter is commonly a second-
line regimen. 
We created a composite index of wealth 
(socio-economic status) using principle component 
analysis (PCA) because it is the most-suitable 
choice to use when calculating wealth indices from 
categorical variables.16 We used PCA on house 
ownership, availability of electricity in the house, 
source of drinking water and fuel used for cooking. 
Scores were obtained and categorized into four 
groups (quartiles) ranging from the poorest to the 
least poor. 
The interviews were conducted in Lango (the 
main language spoken in the study setting) or in 
English by trained study staff. The interviews followed 
a structured questionnaire with questions on socio-
demographic, reproductive-related and HIV-related 
information. The questions were translated into 
Lango and back translated into English to ensure 
accuracy and minimize interpretation bias. 
2.6. Statistical Analysis
Data were entered by two independent data 
entrants using EpiData software (www.epidata.
dk, version 4.4.3.1) and exported for analysis into 
Stata version 14.0 (StataCorp, College Station, Texas, 








98 women were not enrolled because they:
• had been taking antiretroviral
  drugs for less than 6 months = 97
• did not have a viral load test done = 97
• did not have viral load test results = 1
Figure 1: Study flow chart
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summarized into means and standard deviations and 
if not, were summarized into medians with their 
corresponding interquartile ranges. Categorical 
variables were summarized into frequencies and 
percentages. The proportion of HIV-infected 
pregnant women with detectable viral load was 
estimated and its confidence limits calculated 
using the exact method. We used multivariable 
binary logistic regression to estimate the adjusted 
odds ratios (OR) of the independent variables on 
detectable viral load while controlling for other 
variables like age, education status, person to whom 
HIV status was disclosed and duration of taking ART. 
Initially, all these variables were included in the crude 
analyses. Variables with a p-value of <0.25 and those 
with biological or epidemiological plausibility were 
included in the final model.
2.7. Ethical Approval
Approval to conduct the study was granted by the 
Makerere University School of Medicine Research and 
Ethics Committee, the Uganda National Council for 
Science and Technology and the Norwegian Regional 
Committee for Medical and Health Research Ethics 
in the West. Administrative clearance was granted 
by the Lira district health officer and LRRH. Service 
providers / counsellors at the PMTCT clinic were 
introduced to the study and its procedures and 
were requested to identify, mobilize and link willing 
participants with the research team. Participants 
received verbal and written information detailing the 
purpose and process of the study. All participants 
provided written informed consent confirming 
their voluntary participation in the study. Those that 
declined participation were not penalised or denied 
standard health care. Confidentiality and privacy of 
all data collected was observed during the course of 
the study through restricted access. 
3. RESULTS
3.1. Sociodemographic Characterisitcs 
A total of 518 HIV infected pregnant women were 
screened for eligibility from the antenatal care clinic 
at LRRH (Figure 1) and 420 women were included 
in the analysis. The participants had a mean age of 
30.0 (SD 5.2). Socio-demographic characteristics 
are presented in table 1a. More than half (54.1%) of 
the women were 30 years or more. A total of 197 
(46.8%) had attained formal education for a duration 
of at least six years or more. The majority (95%) of 
the women were married (or cohabiting) and not 
formally employed (60.5%). They were predominantly 
Christian (96.2%) and Lango speaking (90.5%) 
(Tables 1a and 1b). A considerable proportion of 
these women had disclosed their HIV status (98.3%). 
3.2. Outcome Variable 
The majority of the participants had undetectable 
viral load (Table 2). The prevalence of detectable 
viral load (>50 copies/ml) was 30.7% (95% CI: 26.3% 
- 35.4%). Of those with detectable viral load, the 
majority (n=82, 19.5% 95% CI: 15.8% – 23.6%) had 
viral load between 50 and 400 cps/ml. The proportion 
of women with a viral load ≥1000 cps/ml was 8.1% 
(95% CI: 5.7% – 11.1%).
3.3. Covariates
Not belonging to the Lango ethnicity was associated 
with having detectable viral load among HIV infected 
pregnant women. Women belonging to other groups 
of ethnicity were almost twice as likely to have 
detectable viral load as their Lango counterparts 
(Table 3). Women who were on second-line 
treatment regimen were four times likely to have 




One third of our study’s participants had 
detectable viral load which is higher than that 
documented in other studies using the same cut-
off of 50 copies/ml. Studies from South Africa11,14,17 
and Malawi18 documented lower prevalence of 
detectable viral load among HIV infected pregnant 
women ranging from 10% to 23%. Much as various 
studies have demonstrated the association between 
detectable viral load and poor or non-adherence to 
ART,7,19–22 we cannot speculate non-adherence as 
a plausible explanation for the high prevalence of 
undetectable viral load since we did not measured 
non-adherence at this point in time.
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Table 1a: Socio-demographic characteristics of HIV infected pregnant women receiving antenatal care 
at Lira Regional Referral Hospital, Northern Uganda
Characteristics Total  
(N=420)
Undetectable viral load <50 copies/ml 
(N=291)
Detectable viral load ≥50 copies/ml 
(N=129)
n (%) n (%) n (%)
Socio-demographic    
Age 
≤ 20 years 17 (4.0) 10 (3.4) 7 (5.4)
21 – 29 years 176 (41.9) 128 (44.0) 48 (37.2)
≥30 years 227 (54.1) 153 (52.6) 74 (57.4)
Education 
0 – 6 years 223 (53.1) 155 (53.3) 68 (52.7)
7 – 10 years 135 (32.1) 90 (30.9) 45 (34.9)
11 – 13 years 43 (10.3) 31 (10.6) 12 (9.3)
≥14 years 19 (4.5) 15 (5.2) 4 (3.1)
Marital status
Married 399 (95.0) 275 (94.5) 124 (96.1)
Single 21 (5.0) 16 (5.5) 5 (3.9)
Employment status
Employed 166 (39.4) 114 (39.2) 52 (40.3)
Not employed 254 (60.5) 177 (60.8) 77 (59.7)
Religious affiliation
Christian 404 (96.2) 280 (96.2) 124 (96.1)
Moslem 16 (3.8) 11 (3.8) 5 (3.9)
Ethnicity
Langi 380 (90.5) 268 (92.1) 112 (86.8)
Other 40 (9.5) 23 (7.9) 17 (13.2)
Socioeconomic index
Group 1 (poorest) 105 (25.0) 76 (26.1) 29 (22.5)
Group 2 107 (25.5) 73 (25.1) 34 (26.4)
Group 3 145 (34.5) 98 (33.7) 47 (36.4)
Group 4 (least poor) 63 (15.0) 44 (15.1) 19 (14.7)
The cut-off used for detectable viral load will 
also determine its prevalence. The lower the cut-off, 
the higher the prevalence is likely to be. A study in 
Malawi 23 reported a similar prevalence of detectable 
viral load like our study, while researchers from 
Rwanda24 reported a higher prevalence than ours. 
These studies, however, used a lower cut-off. In our 
study, the prevalence of virologic non-suppression 
(>1000 cps/ml) was 8%. Studies in Uganda22 and 
Malawi25 reported a similar prevalence of virologic 
non-suppression among HIV infected pregnant 
women. The low prevalence of virological non-
suppression among women presenting for antenatal 
care in Lira can be used as an argument for the 
success of the universal treatment program in 
maintaining viral suppression and of the progress 
towards the last 90% of the UNAIDS 90-90-90 
target.26 Much as we have achieved the desired 
target for viral suppression today, the cut-off of 1,000 
copies/mL used in Uganda is too high. This puts the 
focus on HIV-infected pregnant women with higher 
virologic profiles and less emphasis on those with 
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Undetectable  viral load 
<50 copies/ml (N=291)
Detectable Viral load  
≥50 copies/ml (N=129)
n (%) n (%) n (%)
Reproductive-related    
Parity
1 – 4 289 (68.8) 203 (69.8) 86 (66.7)
5 – 9 131 (31.1) 88 (30.2) 43 (33.3)
Gestational age (in weeks)
20 – 27 225 (53.6) 158 (54.3) 67 (51.9)
28 – 35 138 (32.9) 94 (32.3) 44 (34.1)
≥ 36 57 (13.5) 39 (13.4) 18 (14.0)
Accompanied to antenatal care by partner
 Accompanied 42 (10.2) 31 (10.6) 11 (8.5)
 Not accompanied 378 (89.8) 260 (89.4) 118 (91.5)
Use of birth control
Did not use 198 (47.1) 136 (46.7) 62 (48.1)
Used 6 months prior to  pregnancy 222 (52.9) 155 (53.3) 67 (51.9)
Type of contraceptive used
None or “safe days” 196 (46.7) 133 (45.7) 63 (48.8)
Effective contraception 224 (53.3) 158 (54.3) 66 (51.2)
Intention to have baby
No 182 (43.3) 127 (43.6) 55 (42.6)
Yes 238 (56.7) 164 (56.4) 74 (57.4)
HIV-related
HIV status disclosure
Disclosed 413 (98.3) 287 (98.6) 126 (97.7)
Not disclosed 7 (1.7) 4 (1.4) 3 (2.3)
Fear about others’ opinion on  HIV status
Had no fear 199 (47.4) 137 (47.1) 63 (48.8)
Had fear 221 (52.6) 154 (52.9) 66 (51.2)
Antiretroviral treatment
Efavirenz-based 370 (88.1) 263 (90.4) 107 (83.0)
Nevirapine-based 39 (9.3) 24 (8.2) 15 (11.6)
Protease inhibitor-based 11 (2.6) 4 (1.4) 7 (5.4)
Duration of antiretroviral treatment 
6 – 36 months 216 (51.4) 160 (55.0) 56 (43.4)
37 – 119 months 180 (42.9) 121 (41.6) 59 (45.7)
≥ 120 months 24 (5.7) 10 (3.4) 14 (10.9)
lower but detectable HIV-1 RNA, and yet it is those 
with detectable viral loads that are likely to translate 
into virologic non-suppression.
It is rather surprising that our study found that 
women who belong to other groups of ethnicity 
other than the Lango ethnicity (that is predominant 
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Table 2: Viral loads of HIV infected pregnant 
women receiving antenatal care in Lira Regional 
Referral Hospital, Northern Uganda





50 to 400 82 19.5
401 to 999 13 3.1
≥ 1000 34 8.1
Table 3: Multivariable analysis of factors associated with a detectable viral load (≥50 copies/ml of HIV 
RNA in the blood)
Variables Unadjusted OR Adjusted OR 
(95% CI) (95% CI)
Age 
≤ 20 years 1.45 (0.53 – 3.95) 0.85 (0.29 – 2.53)
21 – 29 years 0.78 (0.50 – 1.19) 0.73 (0.46 – 1.16)
≥ 30 years 1 1
Education status
0 – 6 years 1 1
7 – 10 years 1.14 (0.72 – 1.8) 1.21 (0.75 – 1.96)
11 – 13 years 0.88 (0.43 – 1.82) 0.85 (0.40 – 1.81)
Tertiary 0.61 (0.19 – 1.90) 0.52 (0.16 – 1.76)
Ethnicity
Langi 1 1
Other 1.77 (0.91 – 3.44) 1.92 (1.05 – 3.90)
Person disclosed to 
Spouse 1 1
Sibling 0.67 (0.36 – 1.22) 0.68 (0.36 – 1.26)
Other 1.2 (0.54 – 2.70) 1.32 (0.57 – 3.05)
Antiretroviral treatment
Efavirenz-based 1 1
Nevirapine-based 1.54 (0.77 – 3.04) 1.25 (0.58 – 2.71)
Protease inhibitor-based 4.3 (1.23 – 14.99) 4.41 (1.13 – 17.22)
Duration of antiretroviral treatment
6 – 36 months 0.72 (0.46 – 1.11) 0.66 (0.41 – 1.06)
37 – 119 months 1 1
≥ 120 months 2.87 (1.20 – 6.85) 2.08 (0.77 – 5.53)
in the study setting) had a higher likelihood of 
having a detectable viral load. A study in Benin27 
found the opposite, that the predominant ethnicity 
of the study setting was more likely to have a 
detectable viral load. More qualitative studies 
are needed in our study context to understand 
reasons for this finding.
We also found that taking a second-line protease 
inhibitor-based regimen increased the odds of having 
detectable viral load, which is quite a common 
finding. Studies in Uganda9 and the United States 
of America28 found that protease inhibitor-based 
regimens were associated with lower probability 
of viral suppression than first-line efavirenz-based 
and nevirapine-based regimens among HIV infected 
pregnant women. However, there was no difference 
in the rate of viral suppression among women using 
protease inhibitor-based regimens and those using 
efavirenz-based or nevirapine-based regimens in the 
postpartum period.9,29,30. This finding also be can be 
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explained further by the concept of reverse causality. 
HIV-infected women will be switched to a second-
line ART regimen because of treatment failure of 
the first-line regimens which is mainly due to non-
adherence.31,32 It is probable that the underlying 
challenges of adherence that forced these women 
onto second-line regimens may be aggravated during 
the use of second-line ART regimens. Non-adherence 
may be influenced by a number of factors and these 
may include side effects to antiretroviral drugs, pill 
burden in the context of pregnancy and increased 
psychosocial stressors related to pregnancy or care 
giving.31
4.2. Limitations
Our study had some limitations. This study was 
done in a hospital setting; therefore, the findings may 
only be generalizable to the study context or those 
similar to it. We did not report any adherence rates 
at this point in time because this is a baseline study 
of a cohort of HIV-infected pregnant women for 
whom adherence to ART will be measured as follow-
up is being done. However, a strength of our study 
is that it is the first to describe virologic profiles 
among HIV-infected pregnant women in Northern 
Uganda and also demonstrates that in fact disparities 
in viral suppression do exist across various groups of 
ethnicity in this study setting. 
5. Conclusion and Global Health 
Implications
HIV-infected pregnant women likely to have 
detectable viral load included those taking a protease 
inhibitor-based regimen and those who were not 
natives of Lira. Having a detectable viral load during 
pregnancy increases the risk of MTCT of HIV. We 
recommend intensified clinical and psychosocial 
monitoring of medication compliance among HIV-
infected pregnant women that are likely to have 
detectable viral load to significantly lower the risk of 
vertical transmission of HIV in Lira specifically those 
taking a protease inhibitor-based regimens and those 
who are non-natives to the study setting. Much as the 
third 90% of the global UNAIDS 90-90-90 target33 
has been achieved in the study setting, the national 
implementation of PMTCT guidelines should be 
inclusive of HIV-infected pregnant women that are 
most at-risk of having detectable viral load in this 
study context and those similar to it. 
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Key Messages
• Detectable HIV-RNA is high among HIV-infect-
ed pregnant women.
• HIV-infected pregnant women likely to have 
detectable viral load included those taking a 
protease inhibitor-based regimen and those 
who were not natives of Lira, Uganda.
• Clinical and psychosocial monitoring of 
medication compliance among HIV-infected 
pregnant women that are likely to have a 
detectable viral load to significantly lower the 
risk of vertical transmission of HIV in Lira spe-
cifically those taking a protease inhibitor-based 
regimens and those who are non-natives to 
the study setting should be intensified.
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Sub-optimal adherence to infant prophylaxis has been associated with mother-to-child-
transmission of HIV. However, the factors associated have not been well characterised in
different settings. This study describes barriers and enablers of adherence to infant prophy-
laxis among 6-week-old HIV exposed infants in Lira district, Northern Uganda.
Methods
This prospective cohort study was conducted from 2018–2020 at the PMTCT clinic at Lira
Regional Referral Hospital and included 472 mother-infant pairs. HIV-infected pregnant
women were recruited, followed up at delivery and 6 weeks postpartum. We used a struc-
tured questionnaire to obtain data on socio-demographic, reproductive-related, HIV-related
characteristics and adherence. Data were analysed using Stata to estimate adjusted risk
ratios using Poisson regression models to ascertain barriers and enablers of adherence to
infant nevirapine prophylaxis.
Results
Barriers to infant adherence are maternal characteristics including: younger age (�20 years
adjusted risk ratio (ARR) = 1.55; 95% CI: 1.1–2.2), missing a viral load test during pregnancy
(ARR: 1.4; 95% CI: 1.1–1.7) and not receiving nevirapine syrup for the baby after childbirth
(ARR = 6.2; 95% CI: 5.1–7.6). Enablers were: having attained �14 years of schooling (ARR
= 0.7; 95% CI: 0.5–0.9), taking a nevirapine-based regimen (ARR = 0.6; 95% CI: 0.4–0.9),
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long-term ART (� 60 months ARR = 0.75; 95% CI: 0.6–0.9), accompanied by a husband to
hospital during labour and childbirth (ARR = 0.5; 95% CI: 0.4–0.7) and labour starting at
night (ARR = 0.7; 95% CI: 0.6–0.8).
Conclusion and recommendations
Despite mothers receiving nevirapine syrup from the health workers for the infant, non-
adherence rates still prevail at 14.8%. The health system needs to consider giving HIV
infected pregnant women the nevirapine syrup before birth to avoid delays and non-adher-
ence. There is need to pay particular attention to younger women and those who recently
started ART.
Introduction
HIV-1 exposed infants (HEI) can get infected with HIV from their mothers during pregnancy,
childbirth or breastfeeding. Over 90% of paediatric HIV infections are through mother-to-child
transmission of HIV-1 (MTCT) [1]. However, giving antiretroviral therapy to the mother and
infant prophylaxis to the infant during breastfeeding are the major interventions in the preven-
tion of mother-to-child transmission of HIV-1 (PMTCT) [2, 3].
Since 2013, the World Health Organisation (WHO) consolidated guidelines on the use of
antiretroviral drugs for treating and preventing HIV infection [3] advocate lifelong antiretrovi-
ral therapy (ART) regardless of immune status for pregnant and breastfeeding mothers in
addition to infant prophylaxis for the baby for 6–12 weeks. A longer duration of prophylaxis is
recommended for high-risk infants born to an HIV infected mother that has a viral load (VL)
greater than 1000 copies/ml [2, 3]. For a high-risk infant, the mother’s VL test should be done
at 12 weeks postpartum and only if < 1000 copies/ml should the infant stop taking nevirapine
(NVP). If the maternal VL is not suppressed by 12 weeks, the infant should continue taking
NVP until the mother’s VL is less than 1000 copies/ml or otherwise continue with NVP until
four weeks after cessation of all breastfeeding [1]. These guidelines have been implemented in
Uganda since 2012 [4]
For these interventions to yield impact in PMTCT, adequate adherence to both maternal
ART and infant prophylaxis are a prerequisite [5]. Challenges in achieving optimal adherence
can be programmatic, maternal- or infant-related. There are programmatic challenges with
linkage of HEIs and their mothers from PMTCT to HIV care [6] and lack of clinic-based HIV
counselling [7]. Maternal-related challenges include forgetfulness, poor adherence and social
or cultural obligations [8]. Infant-related challenges are vomiting of the drug or the baby being
sick [9]. Poor adherence to infant nevirapine prophylaxis may contribute to transmission of
HIV hence identifying barriers to adherence is essential to eliminate MTCT.
Several studies have demonstrated an association between non-adherence to infant nevira-
pine prophylaxis and home deliveries, inadequate antenatal care, mother not receiving the
nevirapine for her baby while at the hospital, misplacing of the baby’s drug, lack of transport
and the mother staying with in-laws [10, 11].
While there are numerous benefits of ART prophylaxis for PMTCT, there are still disparities
in rates of MTCT due to differences in programme settings, systems, support requirements and
context. Varying ART adherence rates in various contexts can also contribute to the disparities
in MTCT rates. Most studies done on adherence to infant nevirapine prophylaxis have been
qualitative and were done under previous treatment paradigms and cannot be compared to
today’s situation. Furthermore, different methods have been used to measure adherence to
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infant NVP prophylaxis like relying on caregivers’ report [12], measuring blood plasma con-
centrations of NVP therapeutic levels [9, 13] and electronic dose monitoring like medication
event monitoring systems (MEMs) where bottle caps are fitted with a microchip that records
the time and date of each bottle opening [14].
The goal set by the Joint United Nations Programme on HIV/AIDS (UNAIDS) of getting
to zero new HIV infections among children is far from being achieved in Uganda [1] since
Uganda’s MTCT rates of HIV have stagnated between 3–4% [15, 16] in the past decade. It is
against this background that we studied barriers and enablers of adherence to infant nevira-
pine prophylaxis to optimise the PMTCT programme in Northern Uganda.
Materials and methods
Study design and setting
This prospective cohort study was conducted between August 2018 and January 2020 at the
PMTCT clinic located within the Lira Regional Referral Hospital (LRRH). This clinic is an
initiative of the Ugandan Ministry of Health where free HIV care and treatment are offered
to HIV-infected pregnant women. These women have to attend several other clinics during
pregnancy and after child birth such as: early infant diagnosis, postnatal, immunisation and
family planning clinics. All these clinics are independent of each other and of the PMTCT
clinic in terms of structural location. The PMTCT clinic receives about 30–50 HIV infected
pregnant women daily. At this clinic, the women receive both their antenatal and routine
HIV care until delivery. Approximately 600 HIV infected women deliver at LRRH annually.
For delivery, women are free to choose any health facility or clinic. However, the nevirapine
syrup for infant prophylaxis can only be provided at the clinic where the woman is registered
for her HIV care. The reason for this is to assess, weigh and classify the baby as ‘high risk’ or
‘not high risk’ and to determine the dosage and duration of prophylaxis. It is rare for mothers
to receive nevirapine syrup elsewhere. There are no stores of nevirapine syrup in the labour
suite and maternity ward. Finally, when the baby is 6 weeks old, the mother-infant pair is
transferred to the early infant diagnosis (EID) clinic for further management. Here, care may
be extended, for instance with DNA PCR testing and viral load monitoring for the baby and
others services as applicable.
Participants and procedures
We consecutively enrolled HIV infected pregnant women who were receiving antenatal care
at LRRH and with a gestational age of 20 weeks or more. After consent, women were inter-
viewed on socio-demographic characteristics, HIV-related information like antiretroviral
regimen, duration and a viral load test done during pregnancy. The interviews were con-
ducted in Lango (the language predominantly spoken in the study setting) and/or English
by trained study staff. The questionnaires were translated into Lango and back translated
into English to minimize information and interpretation bias. The research assistants were
trained, qualified midwives who had experience in conducting research, HIV counselling,
providing antenatal care and taking off blood samples for viral load testing so as to shorten
the waiting time of the mothers in the PMTCT clinic. To minimize loss to follow-up, infor-
mation on telephone contacts and physical address were collected. The women were then
followed up with a telephone interview around the time of delivery. At this point, women
were interviewed on circumstances surrounding labour and delivery like time of onset of
labour, type of delivery, place of delivery, person who supervised the delivery, maternal ART
adherence, if the mother had received NVP syrup from the health worker at delivery and
when the baby ingested the first prophylactic dose. At 6 weeks postpartum, mothers were
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followed up and asked about the infant’s adherence to nevirapine prophylaxis. A total of 472
mother-infant pairs were included in the final analysis, Fig 1. All study visits except the one
around delivery were done at the PMTCT clinic as they coincided with the mothers’ routine
visits for ART care. The 6-week interview was done just before the mother was transferred
to the EID clinic. We, therefore, never got the chance to check for HIV transmission rates at
6 weeks from the DNA PCR results and hence this variable is not included in our analysis.
Sample size estimation
We calculated a sample size for detecting an unknown proportion of infants adhering to infant
prophylaxis using OpenEpi (openepi.com). We assumed a 50% proportion, 80% power, 95%
confidence interval (CI) and 5% precision. The total sample size for this study was 384 HEI.
After adjusting for 10% non-response and another 10% to allow for enough degrees of free-
dom in the multivariable analysis, the final sample size was 464. We included 472 mother-
infant pairs.
Variables
ART duration was recorded in months and any ART duration of � 60 months (5 years)
[17] was classified as long term ART, else as short term ART. Viral load test results during
Fig 1. Study profile.
https://doi.org/10.1371/journal.pone.0240529.g001
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pregnancy were categorised as “<50 copies/ml”, “� 50 copies/ml” and “missing viral
load”. Viral loads <50 copies/ml were referred to as ‘undetectable’ and those �50 copies/
ml as ‘detectable’. The “missing viral load” was either due to having been on ART for less
than 6 months or ineligibility for the annual viral load monitoring. Uganda ART guide-
lines do not include viral load monitoring at delivery. Women whose labour started
between 06.00 hours to 18.59 hours were categorised as “day-time onset of labour” and
else “night-time onset of labour”. Women who delivered in any type of health care setting
were all categorised as “clinic delivery” and otherwise as “non-clinic delivery”. During the
follow-up at the time of delivery, we also asked the mother if and when she had received
the nevirapine syrup for the baby from a health worker and when the baby received the
first dose. We estimated the expected date of delivery using the first day of the last normal
menstrual period, and the research assistants called the mother at 7 days after the expected
date of delivery. If the woman had not delivered yet, another telephone appointment was
scheduled.
The outcome variable of interest was “non-adherence to infant nevirapine prophylaxis”. At
the 6-week visit, we asked the mother, “In the past week, how many days did you miss to give
the baby the nevirapine syrup?” Infants that had missed 0–2 doses of nevirapine syrup were
collectively categorised and labelled as “adhered” and those that had missed three or more
doses were collectively categorised and labelled “non-adherent” [9]. We relied on the mother’s
recall for the measurement of infant adherence to NVP prophylaxis at 6 weeks postpartum [9,
14]. All infants included were brought to the PMTCT clinic by their mothers and so we never
asked the mother if there is any other care giver that administered the nevirapine syrup to the
baby other than the mother herself.
Data analysis and management
Data was doubly entered into EpiData (www.epidata.dk, version 4.4.3.1) and exported for
analysis to Stata version 14.0 (StataCorp, College Station, Texas, U.S.A.). Continuous data,
if normally distributed, was summarised into means and standard deviations and if skewed,
was summarised into medians with their corresponding interquartile ranges (IQR). Cate-
gorical variables were summarised into frequencies and percentages. The incidence of
non-adherence to infant nevirapine prophylaxis was estimated and its confidence limits
calculated using the exact method. Bivariable and multivariable analysis was done using
Poisson regression models / analysis [18]. All variables that had a p-value < 0.25 at bivari-
able analysis and those of biological plausibility were collectively put into a multivariable
model to control for confounding. We estimated unadjusted (RR) and adjusted risk ratios
(ARR) with their corresponding 95% confidence intervals.
Results
Baseline characteristics
The mean age for the HIV positive pregnant women at baseline was 29.4 years (SD 5.4)
(Table 1). Almost half of them were 30 years or more and had at least six years of schooling.
The majority were unemployed and had disclosed their HIV status. More than half of them
had taken ART for at least 5 years and had a viral load <50 copies/ml. All the women had
someone accompanying them during labour and delivery, (Table 2). The majority had a spon-
taneous vaginal delivery in a hospital setting, were given nevirapine syrup by the health worker
and were adherent to their ART.
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Adherent to infant NVP prophylaxis
N = 402 (85.2%)
n (%)
Non-adherent to infant NVP prophylaxis
N = 70 (14.2%)
n (%)
Age
� 20 years 28 (5.9) 20 (5) 8 (11.4)
21–29 years 206 (43.6) 171 (42.5) 35 (50)
30–39 years 225 (47.7) 198 (49.3) 27 (38.6)
� 40 years 13 (2.8) 13 (3.2) 0 (0)
Education
� 6 years 233 (49.4) 195 (48.5) 38 (54.3)
7–13 years 167 (35.4) 141 (35.1) 26 (37.1)
� 14 years 72 (15.2) 66(16.4) 6 (8.6)
Marital status
Married 441 (93.4) 382 (95) 59 (84.3)
Single 31 (6.6) 20 (5) 11 (15.7)
Employment status
Employed 187 (39.6) 161 (40) 26 (37.1)
Unemployed 285 (60.4) 241 (60) 44 (62.9)
Religion
Christian 454 (96.2) 386 (96) 68 (97)
Moslem 18 (3.8) 16(4) 2 (3)
Ethnic group
Lango 430 (91.1) 367 (91.3) 63 (90)
Other 42 (8.9) 35 (8.7) 7 (10)
Parity
0 to 4 337 (71.4) 289 (71.9) 48 (68.6)
5 to 9 135 (28.6) 113 (28.1) 22 (31.4)
Gestational age
20–27 weeks 244 (51.7) 207 (51.5) 37 (52.9)
28–35 weeks 162 (34.3) 140 (34.8) 22 (31.4)
� 36 weeks 66 (14.0) 55 (13.7) 11 (15.7)
HIV disclosure
Disclosed 457 (96.8) 392 (97.5) 65 (92.9)
Not disclosed 15 (3.2) 10 (2.5) 5 (7.1)
Antiretroviral regimen
Efavirenz-based 423 (89.6) 356 (88.6) 67 (95.7)
Nevirapine-based 41 (8.7) 39 (9.7) 2 (2.9)
Protease inhibitor-based 8 (1.7) 7 (1.7) 1 (1.4)
Antiretroviral treatment duration
Short-term (< 60 months) 298 (63.1) 243 (60.5) 55 (78.6)
Long-term (� 60 months) 174 (36.9) 159 (39.6) 15 (21.4)
Viral load count
< 50 copies/ml 264 (56) 233 (58.1) 31 (44.3)
� 50 copies/ml 119 (25.3) 101 (25.2) 18 (25.7)
Missing viral load 88 (18.7) 67 (16.7) 21 (30)
https://doi.org/10.1371/journal.pone.0240529.t001
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Non-adherence among infants at 6 weeks
Based on mothers’ recall, 402 of the infants (85.2%, 95% confidence interval (CI): 81.6%–
88.3%) missed between zero and two doses of their nevirapine prophylaxis in the 7 days prior
to the interview. A total of 70 infants (14.8% 95%CI: 11.7%–18.4%) missed between 3 and 7
doses in the week preceding the interview (Fig 1).
Barriers and enablers of adherence to infant nevirapine prophylaxis
Barriers to adherence to infant nevirapine prophylaxis were the following maternal character-
istics: younger age (�20 years ARR = 1.55; 95% CI: 1.1–2.2), having missed to have a viral load
test done during pregnancy (missing viral load ARR: 1.4; 95% CI: 1.1–1.7) and not receiving
nevirapine syrup for the baby after childbirth (ARR = 6.2; 95% CI: 5.1–7.6). Maternal charac-
teristics that enabled infant nevirapine adherence were maternal characteristics that include:
having attained 14 or more years of schooling (ARR = 0.7; 95% CI: 0.5–0.9), taking a nevira-
pine-based regimen (ARR = 0.6; 95% CI: 0.4–0.9), having taken ART for a longer period of
time (long-term (� 60 months) ARR = 0.75; 95% CI: 0.6–0.9), accompanied by her husband to
hospital during labour and childbirth (husband ARR = 0.5; 95% CI: 0.4–0.7) and having labour
start during the night-time (ARR = 0.7; 95% CI: 0.6–0.8) (Table 3).
Discussion
In our study, we found that non-adherence to infant nevirapine prophylaxis was high, 14.8%.
We relied on the mother or caregiver’s report in measuring adherence of the infant to




Adherent to infant NVP prophylaxis
N = 402 (85.2%)
n (%)
Non-adherent to infant NVP Prophylaxis
N = 70 (14.8%)
n (%)
Onset of labour
Day time 251 (53.2) 210 (52.2) 41 (58.6)
Night time 221 (46.8) 192 (47.8) 29 (41.4)
Attendant during delivery
Mother 89 (18.9) 72 (17.9) 17 (24.3)
Husband 109 (23.1) 102 (25.4) 7 (10)
Mother in law 76 (16.1) 61 (15.2) 15 (21.4)
Sibling 51 (10.8) 45 (11.2) 6 (8.6)
Other 147 (31.1) 122 (30.3) 25 (35.7)
Type of delivery
Spontaneous vaginal delivery 413 (87.5) 350 (87.1) 63 (90)
Caesarean section 59 (12.5) 52 (12.9) 7 (10)
Place of delivery
Clinic setting 441 (93.4) 379 (94.3) 62 (88.7)
Non-clinic setting 31 (6.6) 23 (5.7) 8 (11.4)
Mother was given NVP syrup for baby at delivery
Given 362 (76.7) 341 (84.8) 21 (30)
Not given 110 (23.3) 61 (15.2) 49 (70)
Maternal adherence to ART
Adhered 329 (69.7) 284 (70.7) 45 (64.3)
Did not adhere 143 (30.3) 118 (29.3) 25 (35.7)
https://doi.org/10.1371/journal.pone.0240529.t002
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nevirapine prophylaxis. Studies done in South Africa [9, 13, 19], have reported levels of non-
adherence to infant nevirapine prophylaxis ranging from 12.3%–30% within which range the
incidence of non-adherence in our study falls. The reported non-adherence rates vary across
study contexts because different methods were used while measuring infant adherence. Studies
that rely on self-reported or caregiver’s report [9, 10] have reported higher levels of non-adher-
ence compared to those that have relied on electronic dose monitoring [9] and plasma
Table 3. Barriers and enablers of adherence to infant to NVP prophylaxis among 6-week-old HIV exposed
infants.
Variable Unadjusted RR (95% CI) Adjusted �RR (95%CI)
Age
� 20 years 1.3 (1.1–1.9) 1.5 (1.1–2.2)
21–29 years 1 1
30–39 years 0.7 (0.6–0.9) 1.1 (0.9–1.4)
� 40 years 0.1 (0.01–0.5) 0.2 (0.03–1.3)
Education
� 6 years 1 1
7–13 years 1.1 (0.9–1.3) 0.9 (0.8–1.1)
� 14 years 0.7 (0.5–0.9) 0.7 (0.5–0.9)
HIV status disclosure
Disclosed 1 1
Not disclosed 2.1 (1.4–3) 1.3 (0.9–1.9)
Antiretroviral regimen
Efavirenz-based 1 1
Nevirapine-based 0.4 (0.3–0.7) 0.6 (0.4–0.9)
Protease inhibitor-based 1.01 (0.4–1.9) 2.03 (0.98–4.2)
ART duration
Short term (<60 months) 1 1
Long term (� 60 months) 0.6 (0.5–0.7) 0.75 (0.6–0.9)
Viral load count
<50 copies/ml 1 1
� 50 copies/ml 1.2 (0.9–1.5) 1.1 (0.9–1.4)
Missing viral load 1.9 (1.5–2.3) 1.4 (1.1–1.7)
Time of onset of labour
Day time 1 1
Night time 0.8 (0.7–0.97) 0.7 (0.6–0.8)
Attendant during labour and delivery
Mother 1 1
Husband 0.5 (0.4–0.7) 0.5 (0.4–0.7)
Mother-in-law 0.8 (0.6–1.1) 0.8 (0.6–1.1)
Sibling 0.8 (0.6–1.1) 0.8 (0.6–1.1)
Other 0.9 (0.7–1.1) 0.9 (0.7–1.2)
Mother was given NVP syrup for baby at delivery
Given 1 1
Not given 6.3 (5.2–7.6) 6.2 (5.1–7.6)
Maternal adherence to ART
Adhered 1 1
Not adhered 1.3 (1.1–1.6) 1.1 (0.9–1.3)
�RR>1 refers to barriers, �RR<1 refers to facilitators.
https://doi.org/10.1371/journal.pone.0240529.t003
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concentration of therapeutic levels of nevirapine in the infant’s blood [9, 13]. All these studies
measure adherence to infant nevirapine prophylaxis at different time points; some at birth
and the majority at 6 weeks while factoring in variable recall periods. As much as this scenario
could explain the disparities in rates of non-adherence across the different studies and ours, it
is also likely that actual differences in adherence rates do exist in the different study contexts.
The high incidence of non-adherence to infant prophylaxis in our study could be explained by
the fact that many non-adherent women actually did not receive nevirapine for the baby after
delivery.
For the purpose of this discussion we shall focus on barriers and enablers to infant nevira-
pine adherence that are important for policy. The barriers to infant adherence included youn-
ger maternal age, missed viral load test during pregnancy and mother not receiving infant’s
nevirapine syrup after childbirth. Enablers to adherence included an HEI being born to a
woman who: was well-educated (�14 years of schooling), was taking a nevirapine-based regi-
men, has been on long-term ART, had a night-time onset of labour and was attended to by the
husband during childbirth.
Our study showed that infants born to younger women were less likely to be adherent to
their prophylactic treatment. A number of studies have shown similar findings [5, 9, 12].
Most young mothers in our cohort have taken ART for a shorter duration (less than 6
months). This means that their interface with the healthcare system is limited and that they
have not had time to receive adequate ART adherence counselling and subsequently less
informed about the necessity to adhere to treatment and prophylaxis. This is supported by
the fact that babies born to women on long term ART in our cohort were likely to be more
adherent to prophylaxis than those born to women on shorter duration of ART. This find-
ing further demonstrates that women who have been on ART for longer periods are aware
of the benefits of adherence to ART compared to their counterparts that have been on ART
for shorter periods of time due to their frequent and routine interface with the health care
system. One study [20] also demonstrated that women who have taken ART for shorter
periods were more likely to report side effects of ART and this affected their adherence to
ART. While conducting ART adherence counselling, health workers need to pay attention
to these younger mothers.
In our study, infants born to women who did not receive nevirapine syrup from the
health worker for the baby were likely not to adhere to infant ART prophylaxis. The majority
of the women in our cohort who never received nevirapine for the baby actually had a non-
clinic delivery, mostly a home delivery. Studies done in Zambia [13], South Africa [19] and
a systematic review for sub-Saharan Africa [12] have demonstrated the association between
home delivery and non-adherence to infant prophylaxis. Home deliveries have also been
associated with the mother not receiving the nevirapine syrup for the baby from the health
worker at the time of delivery [10, 12]. Women who have delivered at home may not be able
to return to the hospital to pick the infant’s syrup for different reasons. Women who deliver
outside the hospital are also less likely to receive counselling on the importance of their baby
adhering to prophylaxis because they will deliver in the absence of a skilled birth attendant
or health worker. Furthermore, HEIs born to women whose labour started in the night were
more likely to adhere to nevirapine prophylaxis. Most women in our cohort are multiparous
or of higher gravidity. The progress in labour for multiparous women is faster [14]. For
women whose labour begins in the night are most likely to deliver during daytime which
means they will be able to receive NVP syrup for the baby from the health worker at the
PMTCT clinic. The PMTCT clinic is usually closed in the evening and night time in our
study setting. Women who do not receive NVP for the baby are most likely not to administer
it to the baby [12] and this contributes to non-adherence of the HEI to prophylaxis. An
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alternative strategy could be to provide all HIV infected pregnant women with NVP syrup
for the baby from the ANC prior to delivery.
Infants born to women who had not had a viral load test done during pregnancy were less
likely to adhere to the infant prophylaxis. The main reason for this was because they had been
on ART for less than six months [2]. Having had less time in health care, these women have
not yet benefitted from the on-going and continuous ART counselling. Women who have
taken ART for shorter periods of time remain a critical target for adherence counselling.
In our study, it was shown that infants born to educated mothers were more likely to
adhere to their prophylaxis. Educated mothers are more likely to read and comprehend
concepts of adherence taught to them during ART adherence counselling sessions and
therefore are more likely to support their infants with adherence to prophylaxis. Some
studies have shown no association between maternal education and infant adherence to
nevirapine prophylaxis [8] while other studies have shown an association between lack
of maternal education and low infant nevirapine adherence [10, 12] just like our study.
Women who were taking an NVP-based regimen were more likely to have infants that
adhere to infant prophylaxis. In our cohort, women taking NVP-based regimens have taken
ART for longer periods of time. The benefits of taking ART for longer durations have already
been discussed in the earlier paragraphs.
Women who were accompanied to the hospital by their husbands for labour and delivery
were more likely to have infants that were adherent to their prophylaxis. The husband plays
a key role in decision making when it comes to newborn care [21]. Male involvement in
PMTCT generally improves adherence to the whole PMTCT programme. Other studies have
actually demonstrated that male involvement in maternal and child health services promotes
adherence to infant nevirapine prophylaxis [12, 22]. This finding evidently shows that if
PMTCT programs in our study context and those similar to it promoted male involvement,
this would not only enhance adherence to infant prophylaxis but to also the entire PMTCT
cascade of interventions.
Strengths and limitations
Most studies that have been conducted on this subject have been qualitative in nature. With
this prospective cohort study we could explore these associations.
We relied on the mother’s or caregiver’s report for measuring adherence. Measuring medi-
cation adherence while relying on self-reporting varies is influenced by how questions are
phrased and the period of recall. Our adherence estimates are likely to be over-estimated due
to the recall bias and social desirability imposed by the self-reporting [13, 14]. However, other
studies have demonstrated correspondence between relying on self-reports and other mea-
sures of adherence [9, 23].
Most studies have been conducted in urban settings. Our study was done in a rural context
and our findings may only be generalizable to contexts similar to it. The definitions of adher-
ence adopted, the methods used to measure it and recall periods varied across different studies.
Therefore, comparing findings across these studies was rather difficult. We did not measure
the infant’s adherence continuously from birth to six weeks of age considering the limitations
of recall over such a long period of time. We also never included infant-related factors like
infant refusal or illness that influence adherence to infant prophylaxis.
Conclusion and recommendations
Despite many mothers receiving nevirapine syrup from the health workers for the infant, non-
adherence rates still prevail. The barriers to adherence to infant NVP prophylaxis were in
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order of importance: mother not receiving nevirapine syrup for the baby after delivery, young
maternal age and having missed to have a viral load test during pregnancy. The health system
needs to consider to give HIV infected pregnant women the infant nevirapine syrup before
birth to avoid delays and non-adherence. There is also a need to pay particular attention to
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Exclusive breastfeeding among HIV exposed infants from birth to 14 weeks of 
life in Lira, Northern Uganda: a prospective cohort study
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ABSTRACT
Background: Breastfeeding is important for growth, development and survival of HIV 
exposed infants. Exclusive breastfeeding reduces the risk of morbidity, mortality and increases 
HIV free survival of infants. Evidence on risk factors for inappropriate breastfeeding in 
Northern Uganda is limited.
Objective: This study determined the risk factors for non-exclusivity of breastfeeding in the 
first 14 weeks of life.
Methods: This prospective cohort study was conducted among 466 mother-infant pairs 
between August 2018 and February 2020 in Lira district, Northern Uganda. HIV infected 
pregnant women were enrolled and followed up at delivery, 6- and 14- weeks postpartum. 
We used a structured questionnaire to obtain data on socio-demographic, reproductive- 
related, HIV-related characteristics and exclusive breastfeeding. Data were analysed using 
Stata version 14.0 (StataCorp, College Station, Texas, USA.). We estimated adjusted risk ratios 
using modified Poisson regression models.
Results: The proportion of HIV exposed infants that were exclusively breastfed reduced with 
increasing age. Risk factors for non-exclusive breastfeeding included infants being born to 
HIV infected women who: were in the highest socioeconomic strata (adjusted risk ratio = 1.5, 
95%CI: 1.01– 2.1), whose delivery was supervised by a non-health worker (adjusted risk 
ratio = 1.6, 95%CI: 1.01– 2.7) and who had not adhered to their ART during pregnancy 
(adjusted risk ratio = 1.3, 95%CI: 1.01– 1.7).
Conclusions: HIV infected women: with highest socioeconomic status, whose delivery was 
not supervised by a health worker and who did not adhere to ART were less likely to practice 
exclusive breastfeeding. We recommend ART adherence and infant feeding counselling to be 
emphasised among HIV infected women who are at risk of having a home delivery, those 
with poor ART adherence and those of higher socioeconomic status. We also recommend 
integration of these services into other settings like homes, community and work places 
instead of limiting them to hospital settings.
Abbreviations: HIV: Human Immunodeficiency Virus; ART: Antiretroviral therapy; HEI: HIV 
exposed infant; PMTCT: Prevention of mother-to-child transmission of HIV; MTCT: Mother-to- 
child transmission of HIV; AFASS: Acceptable, Feasible, Affordable, Sustainable and Safe; LRRH: 
Lira regional referral hospital; CI: confidence interval; ARR: Adjusted risk ratio; SD: Standard 
deviation; PCA: Principal component analysis
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Background
Breastfeeding is important for growth, development 
and survival in children [1]. In HIV exposed infants 
(HEIs), exclusive breastfeeding is very important 
because they are more prone to diarrhoea, pneumo-
nia, malnutrition and even death [2] compared to 
unexposed infants. Various studies have demon-
strated the positive impact of breastfeeding on child 
survival. A number of studies have shown the benefits 
of breastfeeding which include: lowered risk of inci-
dence and death from infections like diarrhoea and 
pneumonia [3,4] as well as reduced risk of hospitali-
sation [5]. Mixed feeding, when compared with 
exclusive breastfeeding, increases the risk of morbid-
ity and HIV transmission by four fold [6,7] in addi-
tion to reducing HIV free survival among HEI [3]. 
Human breast milk contains various immunoglobu-
lins, proteins, hormones, growth factors, lipids, car-
bohydrates and microbiota that play a very important 
role in the immunomodulation, immune-regulation 
as well as defence against pathogenic bacteria and 
viruses for the infant/neonate [8]
Guidelines from the World Health Organisation 
[1,9] and the Ugandan Ministry of Health [10] recom-
mend that an HIV infected woman should breast feed 
her baby exclusively for the first 6 months and 
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continue breastfeeding till the baby is 12–24 months of 
age while introducing appropriate complimentary 
foods. In cases where exclusive breastfeeding is not 
possible, exclusive replacement feeding is recom-
mended provided it follows the AFASS criteria mean-
ing it should be Acceptable, Feasible, Affordable, 
Sustainable and Safe. Women living with HIV who 
are lactating should take antiretroviral therapy (ART) 
regardless of their CD4 count and should be adherent 
to it [1]. ART helps to prevent HIV transmission 
during the phase of exclusive breastfeeding in the 
first 6 months of life and also during mixed feeding 
thereafter [11].
Barriers to breastfeeding include maternal factors 
like breast problems, home delivery [12], lack of safe 
water, cultural beliefs [13] and lack of counselling or 
support during continuation of infant feeding [6] as 
well as infant factors such as mouth ulcers [11]. 
Interventions such as counselling tend to improve 
exclusive breastfeeding rates [3], however, their 
implementation has to be broad based and should 
cover a wide range of settings such as homes, health 
facilities, communities and work places so as to yield 
a higher impact on breastfeeding.
Several studies have shown low rates of exclusive 
breastfeeding among HEI [6,11,12,14-16]. Risk factors 
for these low rates are not well understood and vary 
with in different contexts. The settings for these studies 
have been heterogeneous and tend to vary from country 
to country. Very few studies have been done in Uganda, 
particularly Northern Uganda. There is limited informa-
tion on risk factors for inappropriate breastfeeding by 
HIV infected women in Lira, Northern Uganda. 
Therefore, our study aimed to determine the risk factors 
for non-exclusive breastfeeding in the first 14 weeks of life 
among HEIs.
Methods
Study design and setting
A prospective cohort study was done in Lira, Northern 
Uganda between August 2018 and February 2020 at the 
Prevention of Mother-to-Child Transmission (PMTCT) 
of HIV clinic in the Lira Regional Referral Hospital 
(LRRH). Lira is home to over 400,000 people who are 
predominantly Langi. It has a diversified economy char-
acterised mainly by farming, brick making, boda boda 
(motorcycle) public transportation and pottery [17]. 
Northern Uganda, particularly Lira, has a very high 
antenatal HIV prevalence of 13.5% [18] which directly 
translates into a higher risk of mother-to-child transmis-
sion (MTCT) of HIV. The PMTCT clinic is an initiative 
of the Ugandan Ministry of Health where free HIV care 
and treatment is offered to HIV-infected pregnant and 
lactating women. Within this clinic, antenatal care is 
offered for HIV infected pregnant women every day of 
the week with the exception of weekends. On a daily 
basis, health education is given in group sessions only 
early in the morning to mothers who have come for 
antenatal care. Health education topics include infant 
feeding in the context of HIV, adherence to ART, viral 
load testing, maternal nutrition and malaria prevention.
Participants and procedures
This study involved HIV infected women and their 
infants. At baseline, HIV infected pregnant women who 
were receiving antenatal care at LRRH with a gestational 
age of 20 weeks or more were consecutively enrolled onto 
the study and interviewed on socio-demographic and 
HIV-related information. A viral load test was done dur-
ing any stage of pregnancy. The date of delivery was 
estimated using the palpation method, gestational wheel 
and first day of the last normal menstrual period. These 
women were then followed up with a telephone interview 
around the time of delivery. This follow-up visit was 
estimated at 7 days after the expected date of delivery. If 
the woman had not delivered yet, another telephone 
appointment was scheduled. At this point, women were 
interviewed on circumstances surrounding labour and 
delivery such as time of onset of labour, type of delivery, 
place of delivery, person who supervised the delivery, if 
the baby received any prelacteal feeds as well as maternal 
ART adherence. At 6 weeks postpartum, mothers were 
followed up with a face-to-face interview and asked about 
the infant’s adherence to nevirapine prophylaxis and 
exclusivity of breastfeeding. When the infant was 
14 weeks of age, women were also asked about exclusivity 
of breastfeeding through a face-to-face interview. We 
used a 7-day recall for and obtained information about 
exclusivity of breastfeeding at the different follow up 
points from when the infant was born to 14 weeks of 
age [19]. All study follow-up visits with the exception of 
delivery were done at the PMTCT clinic. The study visits 
were conveniently planned to coincide with the mothers’ 
ART refills and the infants’ immunisation schedule. We 
scheduled the study visits this way so that the mothers did 
not have to make extra visits to the clinic just for purposes 
of the study and in so doing we saved on extra transpor-
tation costs for the participants.
Sample size estimation
We calculated a sample size for detecting a difference 
between two independent proportions using STATA ver-
sion 14.0 (StataCorp; College Station, TX, USA). We 
assumed 80% power, 95% confidence interval (CI) and 
a 5% precision. We also assumed that 70% of women [20] 
received EBF support and counselling at delivery and that 
42.5% of women were not advised or counselled on 
exclusive breastfeeding during pregnancy [21]. We 
made these assumptions in order obtain the minimum 
sample size required to detect a difference between 
2 A. NAPYO ET AL.
exclusive breastfeeding and non-exclusive breastfeeding. 
The total sample size for this study was 418 HEI. After 
accounting for 10% non-response the final sample size 
was 464. We however, included 466 HEI.
Measurement of variables
Prelacteal feeding was defined as the baby feeding on 
any liquid other than breast milk immediately after 
birth with the exception of medicines like nevirapine 
syrup. The mother was asked, ‘After delivery, did you 
give the baby anything before giving him/her breast 
milk?’ This was a ‘yes’ or ‘no’ response. We, however, 
did not ask which liquids had been given to the baby 
as pre-lacteal feeds. For both the 6-week and 14-week 
visits, the mother was asked, ‘In the past week, have 
you given the baby any liquid or solid food other than 
the breast milk?’ This was also a ‘yes’ or ‘no’ response. 
If the mother’s response was ‘yes’, then she was asked, 
‘What food or liquid did you feed to the baby’. The 
baby was considered to be non-exclusively breastfed 
if the mother had reported giving prelacteal feeds at 
birth or if the mother had reported giving liquids or 
solid food other than breast milk at the 6-week and 
14-week visits with the exception of medicines such 
as nevirapine or supplements like multivitamins.
We also measured maternal ART adherence during 
the follow-up at the time of delivery, we asked the 
mother, ‘In the past week, did you miss taking any 
dose of your medication?’ This was a ‘yes’ or ‘no’ 
response. If the mother answered ‘yes’ she was con-
sidered ‘non-adherent’. We also asked who had 
assisted her during delivery and if she responded that 
it was a nurse, doctor, student nurse, clinical officer, 
midwife, all these responses were categorised into one 
group and labelled ‘birth supervised by health worker’. 
If the response was ‘mother-in-law, traditional birth 
attendant, or good samaritan’ all these responses were 
categorised together and labelled ‘birth supervised by 
non-health worker’
We created a composite index of wealth (socio- 
economic status) using principle component analysis 
(PCA). We used PCA on house ownership, availability 
of electricity in the house, source of drinking water and 
fuel used for cooking [22]. Scores were obtained and 
categorized into three groups which we refer to as 
strata ranging from the poorest to the least poor.
Data analysis and management
Data were collected using pretested, structured ques-
tionnaires, doubly entered into Epi data (www.epi 
data.dk, version 4.4.3.1) and exported for analysis to 
Stata version 14.0 (StataCorp, College Station, Texas, 
USA.). Only mother-infant pairs with data at the 
three time points of follow-up were included in the 
analysis. Continuous data, if normally distributed, 
was summarised into means and standard deviations 
and if skewed, was summarised into medians with 
their corresponding interquartile ranges. Categorical 
variables were summarised into frequencies and per-
centages. The incidence of non-exclusivity of breast-
feeding was estimated and its confidence limits 
calculated using the exact method. Bivariable and 
multivariable analysis was done using the modified 
Poisson regression model [23]. All variables that had 
a p value < 0.25 at bivariable level and those with 
biological plausibility were entered into the multi-
variable model. Variables that were independently 
associated with non-exclusivity of breastfeeding 
were determined using the confidence limits.
Results
A total of 518 HIV infected women were enrolled on 
to the study and followed up till delivery at which 
point 505 women had given birth to their infants. 
These women then were followed up till 6 weeks 
postpartum at which point 472 women and their 
infants had the required data on exclusivity of breast-
feeding. Complete information was obtained for 466 
mothers by 14 weeks and these were included in our 
analysis. The reasons for loss to follow up of partici-
pants at subsequent visits are explained in the study 
flow chart (Figure 1)
Characteristics of HIV infected pregnant women 
at baseline
Almost fifty per cent of the women were aged 30 years 
or more with a mean age of 29.5 years (Standard devia-
tion (SD) 5.4). Most women were married, unemployed 
and had attained at least 6 years of education (Table 1). 
Figure 1. Study flow chart.
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More than half had been pregnant four times and were 
20– 27 weeks of gestation at enrolment. Most of the 
women had disclosed their HIV status. A considerable 
proportion of them were taking an efavirenz-based regi-
men and more than half had a viral load less than 50 
copies/ml.
Characteristics at birth and 6 weeks postpartum
Most of the mothers had their labour start during 
the day time and had a spontaneous vaginal delivery 
(Table 2). Three quarters of them delivered in 
a hospital setting with most deliveries being super-
vised by a health worker. Almost a third of these 
women did not adhere to their antiretroviral treat-
ment in the week preceding delivery. Thirty per cent 
of 6-week old infants missed receiving one or more 
doses of the nevirapine prophylaxis from their 
mother or caregiver.
Infant feeding practices at delivery, 6 and 
14 weeks postpartum
The proportion of infants that were exclusively breastfed 
reduced with increasing age of the infant (Figure 2). 
Incidence of pre-lacteal feeding at birth was 12.7% 
(95%CI: 9.8–16%) (Table 2). The incidence of non- 
exclusivity of breastfeeding at 6 weeks and 14 weeks 
Table 1. Antenatal baseline characteristics for HIV infected women in the study in relation to 
breastfeeding at 14 weeks postpartum.
Total 
N = 466 
n (%)
Exclusive breastfeeding at 
14 weeks postpartum N = 266 
n (%)
Not exclusive breastfeeding at 




≤ 20 years 27 (5.8) 13 (4.9) 14 (7)
21– 29 years 202 (43.3) 120 (45.1) 82 (41)
≥ 30 years 237 (50.9) 133 (50) 104 (52)
Education status 0.9
≤ 6 years 229 (49.1) 131 (49.3) 98 (49)
7– 13 years 166 (35.6) 96 (36.1) 70 (35)
≥ 14 years 71 (15.3) 39 (14.6) 32 (16)
Marital status 0.9
Married 435 (93.4) 248 (93.2) 187 (93.5)
Single 31 (6.6) 18 (6.8) 13 (6.5)
Employment status 0.1
Employed 189 (40.6) 100 (37.6) 89 (44.5)
Unemployed 277 (59.4) 166 (62.4) 111 (55.5)
Religion 0.04
Christian 448 (96.1) 260 (97.7) 188 (94)
Moslem 18 (3.9) 6 (2.3) 12 (6)
Ethnic belonging 0.8
Lango 424 (90.9) 243 (91.4) 181 (90.5)
Other 42 (9.1) 23 (8.6) 19 (9.5)
Parity 0.8
1 to 4 329 (70.6) 189 (71.1) 140 (70)
5 to 9 137 (29.4) 77 (28.9) 60 (30)
Gestational age 0.3
20– 27 weeks 243 (52.2) 133 (50) 110 (55)
28– 35 weeks 158 (33.9) 98 (36.8) 60 (30)
≥ 36 weeks 65 (13.9) 35 (13.2) 30 (15)
HIV disclosure 0.8
Disclosed 451 (96.8) 257 (96.6) 194 (97)
Not disclosed 15 (3.2) 9 (3.4) 6 (3)
Socioeconomic strata 0.06
Lowest 164 (35.2) 105 (39.5) 59 (29.5)
Middle 147 (31.5) 82 (30.8) 65 (32.5)
Highest 155 (33.3) 79 (29.7) 76 (38)
Antiretroviral regimen 0.7
Efavirenz-based 420 (90.1) 237 (89.1) 183 (21.5)
Nevirapine-based 38 (8.2) 24 (9.0) 14 (7)
Protease inhibitor- 
based
8 (1.7) 5 (1.9) 3 (1.5)
Antiretroviral treatment duration 0.08
≤ 6 months 82 (17.6) 46 (17.3) 36 (18)
7– 30 months 101 (21.7) 50 (18.8) 51 (25.5)
31– 119 months 251 (53.8) 146 (54.9) 105 (52.5)
≥ 120 months 32 (6.9) 24 (9) 8 (40)
Viral load count 0.7
<50 copies/ml 264 (56.8) 150 (56.6) 114 (57)
50– 400 copies/ml 76 (16.3) 43 (16.2) 33 (16.5)
401– 499 copies/ml 12 (2.6) 8 (3) 4 (2.0)
>1000 copies/ml 27 (5.8) 18 (6.8) 9 (4.5)
missing viral load 86 (18.5) 46 (17.4) 40 (20.0)
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postpartum were 22.5% (95%CI: 18.8–26.6%) and 
42.9% (95%CI: 38.3–47.5%) respectively (Table 3). By 
the time the infants were 14 weeks of age, almost half of 
them were not exclusively breastfeeding (Table 3).
Risk factors for non-exclusivity of breast feeding 
at 14 weeks of age
Women who were in the highest socioeconomic 
strata were 50% more likely to give their infants 
liquids other than breast milk when compared to 
those in the lowest socioeconomic strata (Adjusted 
Risk ratio (ARR) = 1.5, 95%CI: 1.01– 2.1). Women 
whose delivery was supervised by a non-health 
worker were 60% more likely to practice mixed feed-
ing when compared to those whose delivery had been 
supervised by a health worker (ARR = 1.6, 95%CI: 
1.01– 2.7). Women who had not adhered to their 
ART during pregnancy were also likely to practice 
mixed feeding for their infants when compared to 
their adherent counterparts (ARR = 1.3, 95%CI: 
1.01– 1.7) (Table 4).
Table 2. Characteristics for HIV infected pregnant women and HIV exposed infants at the time 
of delivery and 6 weeks postpartum.
Total 
N = 466 
n (%)
Exclusive breastfeeding at 14 weeks 
postpartum N = 266 n (%)
Mix feeding at 14 weeks 
postpartum N = 200 n (%) P-value
AT DELIVERY
Time of onset 
of labour
0.5
Day time 243 (52.2) 135 (50.8) 108 (54)
Night time 223 (47.8) 131 (49.2) 92 (46)
Type of delivery 0.06
Spontaneous 
vaginal
409 (87.8) 240 (90.2) 169 (84.5)
Caesarean 
section




Hospital setting 435 (93.4) 251 (94.4) 184 (92)
Non hospital 
setting
31 (6.6) 15 (5.6) 16 (8)
Person who supervised 
delivery
0.05
Health worker 436 (93.6) 254 (95.5) 182 (91)
Non health 
worker





Yes 59 (12.7) 0 (0) 59 (29.5)
No 407 (87.3) 266 (100) 141 (70.5)
Maternal adherence to 
antiretroviral treatment
0.06
Adhered 325 (69.9) 195 (73.3) 130 (65.3)
Did not adhere 140 (30.1) 71 (26.7) 69 (34.7)
AT 6 WEEKS 
POSTPARTUM
Infant adherence to 
nevirapine prophylaxis
0.03
Adhered 317 (68.1) 192 (72.2) 125 (62.5)
Did not adhere 149 (30.1) 74 (27.8) 75 (37.5)





361 (77.5) 266 (100) 95 (47.5)
Mixed feeding 105 (22.5) 0 (0) 105 (52.5)
Figure 2. Infant feeding practices among HIV exposed infants 
by HIV infected lactating women.
Table 3. Feeds given to HIV exposed infants at 6 weeks and 
14 weeks postpartum.
Feeds given to infants 
at 6 weeks 
postpartum (N = 466)
Feeds given to infants 
at 14 weeks 
postpartum (N = 466)
Type of infant’s feed n % n %
Only breast milk 361 77.5 266 57.1
Honey 55 11.8 44 9.4
Water 23 4.9 36 7.7
Cow’s milk 13 2.8 70 15
Soup 6 1.3 17 3.7
Porridge 5 1.1 21 4.5
Infant formula 3 0.6
Juice 11 2.4
Solid food 1 0.2
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Discussion
The proportion of infants that were exclusively 
breastfed reduced with increasing age of the infant 
and by 14 weeks of age, almost half of the infants were 
not exclusively breastfeeding. We found a low incidence 
of EBF among 14 week-old HEIs probably because their 
mothers perceive that their breast milk is so insufficient 
that it will not satisfy the baby and so resort to other 
foods as feeding options for the infant such as cow’s 
milk, water and porridge [21]. Cultural beliefs sur-
rounding breastfeeding also influence infant feeding 
practices, for example, believing that giving the baby 
honey will protect them against false teeth and colic 
pain [24]. Giving the baby prelacteal feeds also contrib-
uted to the incidence of non-EBF. Studies from South 
Africa [6] and Nigeria [14] report a similar trend in 
exclusive breastfeeding among HIV exposed infants as 
they grow older. Some systematic reviews [12,16] and 
observational studies [11,15] have reported rates similar 
to that in our study. However one study from Tanzania 
[25] reported a higher prevalence of exclusive breast-
feeding than our study. These disparities could be 
explained by the fact that all these studies included 
infants of varying ages and were done in different socio- 
cultural contexts.
It was common for mothers to give their infants 
prelacteal feeds after delivery. Women are most likely 
to give their babies prelacteal feeds because of sore 
breasts, perceived insufficient milk flow immediately 
after delivery, social and cultural issues like discarding 
of colostrum [21]. Several studies of HEI infants [11] 
demonstrate that mothers give infants these feeds due 
to insufficient breast milk shortly after delivery, because 
of breast problems or maternal death. One study from 
Northern Uganda, a context similar to our study, 
showed that lactating women discard colostrum shortly 
after delivery because they culturally perceive it to be 
dirty and harmful to the baby [21]. This could possibly 
explain why infants in our cohort were given prelacteal 
feeds. An infant missing out on colostrum misses out on 
the essential benefits like building up of their immune 
system and lining of the infant’s gut to keep pathogens 
at bay. This is a potential risk for mother-to-child 
transmission of HIV and development of opportunistic 
infections.
In our cohort, women of the highest socioeco-
nomic status were more likely not to exclusively 
breastfeed their infants when compared to those in 
the lowest socioeconomic strata. One study [26] 
demonstrated an association between socioeconomic 
status and exclusive breast feeding. Most women in 
the top most socioeconomic strata in our cohort were 
actually employed and probably had to return to 
work shortly after delivery because of work-related 
demands and pressures. Furthermore, because of 
work-related demands these women are more likely 
not to receive adequate antenatal care and infant 
feeding counselling and this could explain the finding 
in our study. In our study setting, infant feeding 
counselling has also not been integrated with work- 
place environments. Therefore, women with busy 
work schedules are less likely to receive infant feeding 
counselling.
Table 4. Risk factors for non-exclusivity of breastfeeding among HIV exposed infants at 
14 weeks postpartum.
Unadjusted RR (95% CI) Adjusted RR (95% CI)
Age
≤ 20 years 1.2 (0.7 – 2.1) 1.1 (0.6 – 2)
21 – 29 years 0.9 (0.7 – 1.2) 0.8 (0.6 – 1.2)
≥ 30 years 1 1
Education status
≤ 6 years 1 1
7 – 13 years 1.0 (0.7 – 1.3) 0.9 (0.7 – 1.3)
≥ 14 years 1.1 (0.7 – 1.6) 1.01 (0.7 – 1.5)
Parity
0 to 4 1 1
5 to 9 1.01 (0.8 – 1.4) 1.0 (0.7 – 1.4)
Socioeconomic status
Lowest 1 1
Middle 1.2 (0.9 – 1.8) 1.3 (0.9 – 1.8)
Top 1.4 (0.9 – 1.9) 1.5 (1.01 – 2.1)
Antiretroviral treatment duration
≤ 6 months 1 1
7 – 30 months 1.2 (0.8 – 1.8) 1.27 (0.8 – 2)
31 – 119 months 0.9 (0.7 – 1.4) 1.0 (0.7 – 1.6)
≥ 120 months 0.6 (0.3 – 1.2) 0.6 (0.3 – 1.3)
Person who supervised delivery
Health worker 1 1
Non health worker 1.4 (0.9 – 2.3) 1.6 (1.01 – 2.7)
Maternal adherence to antiretroviral treatment
Adhered 1 1
Did not adhere 1.2 (0.9 – 1.7) 1.3 (1.01 – 1.7)
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Women whose delivery was supervised by a non- 
health worker were less likely to exclusively breast-
feed and were likely to have had a home delivery. 
Having a home delivery deprives the mother of inter-
facing with the health worker and healthcare there by 
losing out on the benefits of counselling and support 
for exclusive breastfeeding. Some systematic reviews 
[3,12,16] and observational studies [11,15,21] showed 
that women who attended antenatal care clinics, 
those that delivered in a hospital and those that had 
infant adherence counselling were more likely to 
practice exclusive breastfeeding. In a hospital setting, 
there is on-going infant feeding training for the 
healthcare worker and infant feeding counselling for 
the mother. Another study from Northern Uganda 
[24] found that health workers were key decision 
makers when it came to breastfeeding. These findings 
from various studies clearly explain why a mother 
whose delivery is not supervised by a health worker 
is most likely not to exclusively breastfeed her infant. 
In light of this, it is important that infant feeding 
counselling is introduced in a combination of settings 
and not only at health facilities: such as at the facility, 
work place, community and home settings.
Our study demonstrated that women who had not 
adhered to ART during pregnancy were also likely not 
to exclusively breastfeed their infants. Being non- 
adherent to ART is an aftermath of not interfacing 
routinely with the healthcare system [27]. Therefore, 
these women will not achieve the benefits of this rou-
tine interaction with the healthcare system like contin-
ued counselling on infant feeding. Women who are 
non-adherent to ART will hence most likely not be 
adherent to infant feeding guidelines and will not 
exclusively breastfeed their infants. Non-adherence to 
ART will lead to higher viral loads and advanced HIV 
disease which poses a high risk for transmission of HIV 
from a mother to her baby during breastfeeding. Few 
studies have examined antiretroviral adherence during 
pregnancy and its association with infant feeding prac-
tices. However, pregnancy in itself has been associated 
with low ART adherence [28]. Drug-related factors 
such as side effects and pill burden as well as physio-
logical changes during pregnancy are barriers to ART 
adherence [29]. More qualitative studies should be 
done to shed more light on the association between 
ART adherence and breastfeeding.
Strengths and limitations
This study had some strength. The fact that this is 
a prospective cohort study has helped to establish caus-
ality between various covariates and non-exclusivity of 
breastfeeding. Most studies that have been conducted 
on this subject matter have been cross-sectional in 
nature and only show associations. Showing causality 
for inappropriate infant feeding paves the way to the 
designing of interventions to promote exclusive breast-
feeding. We also measured exclusive breastfeeding con-
tinuously from birth and also relied on a 7-day recall 
which is likely to avoid exaggeration of the incidence of 
exclusive breastfeeding in our cohort. To minimize loss 
to follow-up, we documented the telephone contacts 
and residential mapping of each participant. Instances 
where we could not reach the participant on phone, we 
made a home visit and this resulted into a high com-
pletion rate of 94%.
Our study had some limitations. This study was 
done among HIV infected women attending a public 
health facility therefore our findings may not be gen-
eralizable to women attending clinics that are private- 
for-profit and private-not-for profit. We measured 
exclusive breastfeeding at 6 and 14 weeks using 
a 7-day recall of the mother or care giver. This can 
potentially be a source for recall bias.
Conclusion
The proportion of exclusively breastfed HEI reduced 
with increase in the infant’s age. HIV infected women 
with highest socioeconomic status, those whose deliv-
ery was not supervised by a health worker and those 
that who did not adhere to antiretroviral treatment 
were likely not to exclusively breastfeed their infants. 
We recommend ART adherence and infant feeding 
counselling to be emphasised and integrated in 
a diverse settings such as homes, work places, com-
munities and health facilities.
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